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( 士 ) - Y u e h c h u k e n e (YCK) is a novel non-oxygen bis-indole 
alkaloid isolated from the roots of Murraya paniculata (L.) 
jack and exhibited potent anti-implantation activity in ra ts . 
Yuehchukene is now obtainable by synthesis. Structural 
modification of i t s tetracyclic ring and analogues synthesis 
were carried out in order to define the structural 
requirements for i t s biological activity. Stereo-selective 
synthesis of R(+)- and S(十camphor-YCK showed that R(+)_ 
enantiomer was active in both anti—implantation and 
uterotrophic activity assay. YCK binds to uterine cytosol and 
displaces labeled estradiol as well as labeled tamoxifen in 
liver microsomal prepaxation. YCK behaves -like a weak 
estrogen in ornithine decarboxylase activity assay and i t 
could no 七 fully stimulate the response as induced by 
diethylstilbestrol in glucose-6-phosphate dehydrogenase 
activity assay. YCK has a direct anti一proliferative effect in 
MCF-7 breast cancer cell、line showing that i t might act like 
an anti-estrogen. By-modifying-the natural design of YCK, we 
can have a new chemical probe to study the dissociated 





1.1 Phytochemistry and Phylogeny 
Yuehchukene (1) (YCK) is a novel bis-indole 
alkaloid isolated from the root of Murrava paniculata (L.) 
jack, Rutaceae (Fig. 1). YCK exists in less than 20 ppm and 
is unstable in i t s pure form. Before YCK was discovered by 
Kong et al-‘, (19 85a)七he genus Murrava was well known for the _ 
carbazole alkaioids they contained (Kapil, 1971; Chakraborty, 
1977) • The predominant- phytochemical constituents in Murraya 
and other species of Rutaceae are no doubt 七he_ coumarins 
(Fig. 2) (Gray and Waterman, 1 9 7 8 , . Waterman, 1983) . Both 
carbazoles and coumarins could be easily extracted and 
purified in crystal forms. Thus YCK has always escaped, the 
attention of phytochemists. I t could not be discovered except 
. - - ...-- -、 
by the dedicated effor t 七 o look for oral-active ant i -
implantation agents from plant sources. 
Yuehchukene (1) ’ 卞 H 10 > 
7' j-j
1
 * Chiral centres 
Fig. 1 : Yuehchukene 6召-（工ndol-31-yl)-7,7,9-trimethyl-
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Fig. 2 : Structure of yuehchukene and other compounds in 
Murraya spp and related compounds in other species. 
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An alcohol extract of the root from Murray a 
paniculata could effectively prevent gestation in rats. Since 
i t was only effective when dosed from Pregnancy Day 1 to 4, 
this extract contained an anti-implantation agent (Kong et 
a i . f 1985b)• Using this bioassay model to guide the 
purification steps/ YCK was finally obtained in sufficiently 
pure form for structure elucida七ion (Cheng et al, , 1985). 
This mode of operation, magnified 50 times, describes grosso 
modo the scope of mission-orientated research carried out in 
the Hong Kong Centre, based in the Biochemistry Department, 
CUHK.工七 formed part of "A Multi—Centre Collaborative 
Approach for 七he Isolation of Fertility Regulating Agents 
from Plants", sponsored by the World Health Organisation 
(W.H.O.), Special Programme of Research, Development and 
Research Training in Human Reproduction. 
This colossal research undertaking, which lasted 
over 10 years with a total funding of US$10 million and 
involving more than 100 scientists from a dozen countries 
will form the subject of a monograph due to be published in 
* • 
mid-1992. The most tangible result coming out of this 
herculean task is the discovery and synthesis of YCK. A 
patent was approved for using YCK as "Ferti l i ty Regulating 
Agents
11
 —一 European Patent No. 84304243.1 assigned to Yun 
Cheung Kong, citing priority date 23-06-83. Because YCK was 
not active in marmosets, and a handful of YCK analogues did 
3 
I 
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not give better results, W.H.O. is no longer developing YCK 
as an anti-fert i l i ty agent after 1988. This thesis is devoted 
to the structure-activity relationship study of YCK and i ts 
analogues carried out after W.H.O. funding had ceased. The 
ultimate objective is to evaluate the estrogenic activity of 
YCK-type molecules and to assess to what extent these 














While the most obvious attribute of YCK concerns 
i t s anti-implantation activity, the compound i t se l f presents 
several unique chemical features : 
1. YCK has an indeno-indole basic structure not 
- found in any other indole derivatives (Fig. 
3a), 
2. YCK is the product of dimerisation from two 
prenylated indoles (Fig. 3b), 
3 . YCK could be considered a bis-indole joint by 
a methylene bridge (Fig. 3c), 
4 u YCK is most likely a non-enzymatic 
condensation product from i t s precursor (Fig. 
3d). 
Having obtained spectral data from 4 independent 
laboratories in Hong Kong, Tokyo, Glasgow and Auckland, i t 
was s t i l l impossible to assign the definite structure with 
certainty simply because there was no precedent example of 
such molecular design, albeit not too complicated with hind 
sight. The definite structure was finally determined with 3 





C-NMR spectral data with 
borreverine (Fig. 2) (Tillequin and Koch, 
1979), 
2. Biomimetic synthesis, assuming that YCK is the 
5 
dimer of an isoprenyl indole,七he MBDI (3-
；‘ me七hyl一buta一l,3_diene一indole) (Fig. 2) . The 
la t t e r was f i r s t synthesised for th is purpose . 
but later found in nature (Kinoshi七a et a l . , 
- 1985; Kong et a l . , 1988) . MBDI dimerised under 
acidic conditions to give YCK (see Scheme 1) 
(Cheng et a l . , 1985)• A similar approach had 
been described for borreverine (Tillequin et 
a l . , 1978). 
3 • x-ray d i f f r ac t ion of N
1
-monoacetyl 
L derivative from, which, i t was learnt that 
• • . : . ; . • ' '>.；., , . . • ..... . 
although there were 3 chiral centres in YCK, 
the crystal form referred to a racemate in 
which the pair of hydrogen atoms between the 
two rings of the indene moiety are in the c i s -
- configuration and in the same plane as the 
free indole (Kong et a l . , 1985c) (Fig.3) 
18 
. 一 l ^ f . 
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Fig. 4. ： X-ray crystallographic model of yuehchukene. 
6 
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Before entering into SAR discussion of YCK, i t may 
be appiropriate to note 七 h a t the phylogene七ic origin of YCK is 
possibly quite different from that of the carbazoles. 
According to Waterman (Kong et a l . , 1986) YCK may have 
originated from 3-prenylindoles whereas the carbazoles are 
originated from 2-prenylindoles. This divergent phylogenetic 
origin predicts that YCK and carbazoles would not co—exist in 
the same plant which i s indeed the case. Thus by using the 
two compounds as marker molecules, a l l species of the Murraya 
genus could be separated into two groups, viz. section 
Bergera - - - Murrava species containing carbazole alkaloids 
and section Murraya Murrava species containing YCK (But 
et a l . , 1986). This segregation was corroborated by the fact 
七 ha 七 pirenylated indoles were found in M. paniculata 
(Kinoshita et a l . , 1989) and MBDI was found in Merillia 
together ki th YCK (Kong et a l . , 1988). The former author 
t r ied to argue for a common origin for both carbazole and 
YCK, but th is hypothesis l e f t many steps needing data 
support. 
Carbazole alkaloids were prone to be prenylated, 
some even ,with a geranyl addition, and mono-prenyla七ed 
coumarins were plenty, but they did not form dimerised 
products like YCK (Chakraborty, 1977; Gray and Waterman, 
1978). These biogenetic considerations, which constitute 
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phylogeny, shed some light on the conservative nature of YCK 
molecular design. This comes as a mixed blessing for SAR 
studies because on one hand, i t would not be necessary to 
look for minor structural variations in close congeners of 
YCK which are actually non-existent; on the other hand, i t i s 
hard to improve upon the molecular structure afforded by 
nature. This perspective bespeaks much of the constraints and 





1.2 Biological Activity 
The search for an oral-active, non-steroidal (post-
coital) interceptive agent delineates the logist ic approach 
in phytochemical extraction and the selection of bioassay 
models• YCK proved to be a non-polar compound, ye七 permeable 
to the gut barrier, which blocked implantation in 
successfully mated ra ts . Whether YCK is a pro-drug that 
undergoes metabolic transformation prior to the expression of 
biological activity is beyond the scope of th is thesis . 
Suffice to say that :YCK foraula'ted in an oil-based vehicle 
and administered orally could effectively prevent 
implantation at 1.25 mg/kg/ dosing PD". Under similar 
laboratory conditions, i t would require 0.12 mg/kg 17a-
ethynylestradiol to achieve the same effect . The dose 
response curves of the two compounds were entirely paral lel . 
Thus yuehchukene has an apparent relative potency of 
approximately 10% with respect to estradiol. Such a potent 
natural product estrogen was not known before。 The 
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Since implantation in rats is susceptible to 
estrogen action (Hahn et al. , 1974) and YCK has a very high 
potency compared to estradiol in the present bioassay model' 
the immediate question is to find out if YCK is estrogenic 
and that- the anti-implantation activity of YCK is an 
expression of i ts estrogenicity, The answer to this question 
i s the classical Allen-Doisy test in which estrogenic 
compounds could cause cornification of the vaginal epithelium 
in laboratory rodents. This sensitive but at best semi-
quantitative test is not adequate to evaluate the potency of 
estrogenic compoundsmost of them weaker than E2 (Fig. 5), 
the most .active natural estrogen in human and mammalian 
bodies. A more quantitative, albeit less sensitive test is 
the uterotrophic assay in iinmature female rats. 
When 21-day old female rats are ovariectomised, 
they are considered estrogen-innocent as they are not exposed 
to endogenous estrogens. Whatever endogenous estrogen that 
might have originated 、from internal sources will be 
metabolised during the few days of post-operation recovery. 
Rats thus prepared respond to estrogen treatment by an 
increase in uterine weight with accumulation of uterine 
fluids. This hypertrophy is accompanied by an Increase in 
DNA, RNA and protein syntheses. On a macroscopic scale, i t i s 
sufficient to record the increase in uterine weight (without 
fluids) to construct a calibration curve that stretches 
11 
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several fold over the control (approximately 20 mg/rat). The 
relat ive potency of a t e s t compound administered by the same 
route can be read off th i s scale. Very often, the dose 
required to stimulate the increase in uterine growth by 100% 
is considered the c r i t i ca l doubling dose. Estrogenic 
compounds as weak as l/1000th the potency of E2 could be 
picked up by th is t e s t if suff ic ient quantities are fed to 
the animals. 
YCK was indeed estrogenic according to the resul ts 
of uterotrophic assay, with approximately 4.5% estrogenic 
potency with respect to EE2. However, i t was also noted that 
the dose response curves of YCK and EE2 were not paral le l , the 
former having a slower r is ing slope. Furthermore, the maximum 
response el ic i ted by YCK could only produce half of the 
plateau value reached by 七 he positive control (17a_ 
e七hynylestradiol) , These observations strongly suggested that 
YCK behaved like a par t ia l agonist in estrogen-sensi七ive 
bioassay models. A par t ia l agonist i s different from a weak 
agonist in the sense that the former could not e l i c i t the 
fu l l spectrum of biological responses no matter how much of 





This observation cal ls for a closer examination of 
the anti-implantation resul ts . Whilst uterotrophlc response 
i s the expression of estrogenic act ivi ty in i t s target 
t issues, implantation requires a well-timed tubal transport 
of the zygotes, arriving at a moment of optimal receptivity 
by the uterus. Here the complexity of neuro-endocrine 
regulation, tissue compatibility and maternal adjustment may 
not necessarily result directly from the singular action of 
an estrogenic s ta r t signal. In simple terms, the ant i -
implantation activity manifested by YCK may not be the same 
as the estrogenic activity inherent in YCK as evidenced by 
i t s utero七rophic potency. According to th is reasoning, there 
i s a need to make YCK analogues, or s ter ic isomers since YCK 
is a racemate, in order to find out i f estrogenic and ant i -
implantation act ivi t ies are residing in differervt structuiral 
elements or configurations. Alternatively, if the change in 
uterotrophlc potency is paral lel to a change in ant i -
implantation activity, one might reasonably conclude that the 
anti-implantation of YCK is an expression of i t s 
estrogenicity. 
13 
1.3 Synthetic Estrogens and Anti-Estrogens 
The occurrence of natural estrogens has been 
briefly mentioned above. While is i t rare for a person to 
ingest a lot of natural estrogen like a grazing cat t le to 
in i t i a te an estrogenic response of the body, i t i s entirely 
possible to run into 七he hazards of estrogen pollution by 
eating hormone-loaded meat. The use of hexestrol (Fig. 6a) in 
the poultry industry was a common practice in Hong Kong. 
Diethvlstilbestrol (Fig. 6a) was a widely used estrogen in 
cat t le and sheep (Knight, 1980). Indeed, consumers to-day are 
so accustomed to hormone-fed chicken in taste , texture and 
price, such that free-ranch chicken have no place in a 
competitive market except for the support of enthusiastic 
conservationists. A similar situation prevails in the cat t le 
industry. But here, substantial water exudation when meat 
from a hormone-fed cat t le is cooked (due to water retention 
property of the steroids, not only estrogen) makes i t very 
obvious and abhorrent to an ordinary consumer, even though 
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Fig. 6a ： Structures of some examples of synthetic estrogens 
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Supposing one can be effec七ively protected against 
the pollution of estrogenic compounds from meat sources a七 
the exorbitant price of esting "organic" meat, one can not be 
to ta l ly free from contamination by exogenous estrogenic 
compounds. DDT derivatives like methoxvchlor (Lust et al. , 
1985; Bulgar and Kupfer, 1985) (Fig. 6b) , chlorinated 
insecticide kepone (Jordan et a l . , 1985) (Fig. 6b), fungal 
product zearalenone (Jordan et al , / 1985) (Fig. 6b) are 
estrogenic as well as phenol red which is commonly used as 
indica七or in ce i r culture rBerthois et a l . , 1986) (Fig. 6b). 
By the same token,, phenolic agricultural chemicals like 
herbicides, fungicides, insecticides, nematocides etc. could 
also be estrogenic if there are sufficient research efforts 
to scrutinise them in this regard. So on top of "organic" 
meat, one has to eat "organic" vegetables and drink 
"inorganic" water in order to avoid seepage of estrogenic 
chemical pollutants into water supplies. 
Perhaps what is more alarming is the widespread use 
of synthetic estrogens in health management. The use of 
diethylst i lbestrol (Fig. 6a) as an emmenagogue had been very 
popular. The use of the、same compound for. postmenopausal 
ireplacemeri 七 therapy is s t i l l in currerrt practice, now 
replaced by EE2. I t is now textbook knowledge that pregnant 
women exposed to high dose of DES would give birth to female 
progeny, with a high incidence of vaginal cancer (Bowman and 
17 
Rand, 1980) • DES was known to cause carcinogenic lesions in 
laboratory animal (MaLachlan et a l . r 1980). The positive 
correlation between intrauterine exposure to DES and the 
subsequent development of clear cel l adenocarcinoma of the 
vagina and cervix was upheld in a detailed s t a t i s t i c a l 
analysis (Herbst e t _ a l . , 1986) . Inspite of these 
observations, there have been relent less effor ts to develop 
synthetic anti-estrogenic or estrogenic compounds that could 
serve as an t i - f e r t i l i t y agents. Thus compounds like 
r^ntchroman (Kamboj et a l . , 1977) (Fig. 6a) and 
Hiph^nvlindole (Iyer vand Gopalchari, 1966). (Fig. 6a) were 
、made and abandoned. A twist of fate turns clomifen (Huppert, 
1979) (Fig. 6a) from an an t i - f e r t i l i t y agent into a f e r t i l i t y 
drug (Bowman and Rand, 1980). A more rewarding research 
undertaking came from the synthesis of tamoxifen (Fig. 6a) 
(Robertson and Katzenellenbogen, 1982). Based on a 
七 r i p h e n y l e t h y l e n e design, but with the addition of an 
alkylaminoethoxy side chain on the /3 ring, TAM is a weak 
estrogen with p o t e n t anti-estrogenic properties. This makes 
i t ^ very popular drug to t rea t estrogen-sensitive breast 
cancer. 
An anti-estrogen i s a compound that acts on 七he 
same locus as estrogen but blocks the expression of 
estrogenic activity in target ce l ls . But since a l l currently 




action； there is a need to develop a "pure" anti-estrogen 
such that a massive dose of anti-estrogen will not behave in 
the end like estrogen per se> Thus compounds like LY156758 
( F i g . 6a) was made which claimed less agonistic act ivi ty than 
TAM but showed anti-estrogen action (Black e t a l . f 1983)• The 
gis t of the matter does not l i e in agonist or antagonist 
alone. Binding af f in i ty to estrogen receptor must also be 
considered. An AE would be a ligand with high a f f in i ty 
binding to ER but carrying low estorgenic act ivi ty. This 
serves 七o displace fi occupancy of ER and by the same token 
limits the extent of estrogenic response due to i t s weak 
‘ agonist act ivi ty. According to th i s theory, both E and AE 
compete for the same receptor.-
1 # 4 Es七rogen Receptor and Anti-Estrogen Binding Site 
Hormones are regulatory molecules that are freely 
distributed in the body f luid. I t i s high af f in i ty receptor 
binding that allows a horpone to home-in i t s target 七 i s s u e s . 
Protein and peptide hormones will bind to membrane receptors 
on the cell surface of their target t issues. Steroidal 
hormones are f i r s t bound to plasma carrier proteins of broad 
spectrum specifici ty and moderate a f f in i ty . Because of their 
lipophilic nature, steroids can easily "melt" into the plasma 
membrane, leaving the plasma carrier behind, and translocate 
themselves into the cytoplasmic compartment. A target t issue 
19 
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contain a highly specific cytoplasmic receptor that binds the 
in-coming steroid with much higher a f f in i ty such tha七 the 
steroid molecules are retained within the cell. Without these 
highly specific and high af f in i ty receptors, the steroid 
molecule would "wander" out of the cel l again, be picked up 
by the plasma carrier and vehicles to another target t issue 
or s i t e of degradation. 
Meanwhile, the cytoplasmic receptor-steroid complex 
will undergo a conformational rchange which favours a 
translocation from , the cytoplasmic into the nuclear 
“ compartment. There the complex s i t s on a recognition s i t e in 
the genome, thereby activating the transcription of hormone-
specific genes. A number of biological responses resul t in a 
paral lel as well as radial manner. This is the classical 
description of an estrogen receptor model (Fig. 7A)• 
Recently, there are evidences that the presence of 
cytoplasmic receptor may actually be an ar tefact . The fact is 
that the receptor i s always in the nuclear compartment 
(Dickson e t _ a l . , 1980). Ligand binding permits the 
conformational changes and the retention of the ligand-
receptor complex in the nucleus.工f suff icient care is taken 
to prepare an ill七act nuclear fraction, there will be no 
ligand-receptor complex In the cytoplasm prior to 
conformational change (Fig. 7B)• I t is only due to leakage 
2 0 
. , * I 
• ^ A： 1 ‘ - •:, ‘ 
fc CvcoqJasm "^“ Procai.t 
\ Synches is 
\ .J.： 
V ^ 
• - A 
. • 、劣 
E
 P.N A , • 
PolyfTiaraso 
Pg、. 、 £ 4 - ^ R 











A L — - — — 
E 
Cy top l a sm Protein. 
、 Syn thes i s 
\ ^ 
• •  •允 ；v : mRNA 
V ^ 
• RNA-4IF . 、 T PotYmerasa. 
P -
C ^ / - - - ：-•• _ “ 
/ procassing ？ 
I , ) DNA ^ 
Nuclear Potymaraso , 
=« . [/Agcap.cofs| Fralifaratlon 、 
• •s-zi*^ 
Nucleus 
B L - ： ； ； 
Dynajnia 
of N u c l e a r 
- Receptor- Complex-
3Inding to | ： T. 
AS3S 1 j w ^ Cy too ia sm 1 
^ ^ A J ^ - , • i Protein 
A£ — . i I Synthesis. ” 
s t ^ n ‘ . 
I Estrogorr 
丄 Receptor,州戽 
Altered ^ Rrocas^ing Po l yme r a s e 
Recapcor 
ln t e ra t ion \ i— T' 
Y Nuc l ea r 
• \ l Accapcors I Effect on-
^ L A E R J P o l Y m e r a 3 a . ^ T Proi l fara t ion 
E f f e c t on 
Nuc lea r Recep to r Fornr 
Nucleus 
II I “ I I I • mi I 1 • 
Fig. 7 : A hypothetical model of estrogen receptor (redrawn 
af ter Jordan 1984)• 
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from damaged nuclei that gives r ise to cytoplasmic ligand-
receptor complex. Under normal conditions, the exit of 
unbound nuclear receptors into the cytoplasmic compartment is 
only meant for degradation, no 七 to meet 七 he steroid 
molecules. This modified version of estrogen receptor has no 
bearing on the study of SAR proposed in th is thesis except 
f o r the fact 七 hat the new version leaves room for the 
existence of an anti-estrogen binding s i t e in the cytoplasm. 
According to this hypothesis, AEBS are found in the 
cytoplasm alongside with estrogen binding receptors in the 
nucleus. An AE would bind to both si tes /receptors. An AE 
could cause only altered conformational change of the AE-R 
complex, and in turn activating only part of the biological 
response. Quite independently, AE binds directly to the 
cytoplasmic AEBS, thus mediating the biological response 
relevant to the use of AE； eg. inhibition of cel l growth and 
differentiation in hormone-dependent cancer cell lines. This 
hypothesis allows a more responsible role for AE in cancer 
treatment other ttian by simply displacing estrogen occupancy 
of ER (Fig. 7C) (Jordan, 1984). 
Recently, there are several lines of evidences 
indicating 七he presence of additional estrogen binding s i tes 




In the mouse uterine cytosol high-speed supernate 
(105,000 g), E2 bound to ER under low sal t condi 七 ions 
sedimenting at 8S in sucrose density gradient. This binding 
was completely displaced by an excess of DES or E2. Under the 
same conditions, DES and i t s oxidative metabolite indenestrol 
A (IA) (see page 118) bound to a 4S component with equal 
a f f in i ty . This binding could only toe par t ia l ly displaced by 
DES or E2. This 4S component (Type 工工 E2 binding site) could 
be distinguished from the ER because i t was not recognised by 
specific monoclonal antibody (H-222) to the la t t e r and that 
i t was precipitated by 80% ammonium sulphate (instead of 40% 
for ER) . The binding was not sensitive to dithiothreitol. 
Although Type 工工 binding s i 七 w e r e found in other t issues 
(eg. lung, l iver) , only those from estrogen sensitive 七 i s s u e s 
(eg. pituitary) could be displaced by DES. The presence of 
these Type"工工 binding s i tes could afford an explanation for 
七he development of carcinogenic lesions in the genital t rac ts 
of experimental animals af ter in utero exposure to DES (Chae 
et_al . , 1991)• 、 
Type 工工 estrogen binding s i tes were also found in 
DES-stimulated chick oviduct high speed supernate (105,000 x 
g) • Although i t bound E2 with lower af f in i ty (Kd lOnM) , but 
a sigmoidal binding curve indicated cooperative binding 
mechanism. E^  binding to 七 h i s Type 工工 binding s i tes was 
specifically displaced by luteolin (a flavone) (Fig. 8) which 
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competes avidly with E2 and DES. I t may be added that this 
binding s i te is smaller (molecular weight 40K) than ER, 
sensitive to dithiothreitol and adsorbable on hydroxyapatite 
(Densmore et a l . , 1989)• 
More convincing evidence of the existence of AEBS 
comes from the study of ra t liver microsomal preparation. 
[
3
H]-Tamoxifen binding to this preparation (80,000 g pellet) 
was 50% displaced by N.N-DPPE (Fig. 8) . Although binding 
aff ini ty for N,N-DPPE (Kd 60nM) was weaker than Tam (Kd 
5nM) , Tam bound to a npn-ER binding s i te recognisable by N'N-
DPPE. This compound could be considered as an analogue of 
Tam, but unlike Tam or other AE i t could no七 induce the 
synthesis of progesterone receptor in MCF-7 cells (Brandes, 
1984). 
This microsomal AEBS was not easily discovered 
because of the presence of an endogenous inhibitor (Hwang, 
1986, 1987) . High aff ini ty [
3
H]-Tam binding (Kd 0.8 nM) to 
this s i te iruthe presence of DES ( i .e . non-ER—binding) could 
be displaced by 7-ketocholestanol (Fig. 8). I t is suggested 
that a lipid molecule of similar structure exists in the 
cell ; i t occupies the AEBS unti l a potent AE comes in to take 
i t s place. This s i te is thought to mediate the anti-
proliferative activity of AE (Hwang and Martin, 1989). By 
using a sonicate preparation from MCF-7 cells , the same 
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research group demonstrated that there was a clear positive 
correlation between the relative cytotoxic potencies of 
oxysterols and their a f f in i t i es for this AEBS ([
3
H]-Taro. 
binding in the presence of excess DES) (Lin and Hwang, 1991)• 
A post-mitochondrial preparation from MCF-7 cells 
bound labeled morpho-BPE (Fig. 8) with moderate aff ini ty (Kd 
5 . 4 nM)• This binding could be displaced by cold Tarn but not 
by E2. Furthermore morpho-BPE did not bind to ER. I t is 
suggested that morpho-BPE inhibition of cell growth was 
mediated through this, binding s i te which was not reversible 
by E2 (Poirot et al . , 1990) . This observation was f i r s t 
reported by Sutherland et al . (1986) that Tam、inhibition of 
MCF-7 cell growth manifested a biphasic manner with respect 
to estrogen reversal. At low dose range, inhibition could be 
reversed by E2, but beyond 10"
7
M inhibition was estrogen-
independent. 
We have cited two typical examples from 3 different 
t i s s u e sources ind ica t ing the presence of: 
additional/alternate or anti-estrogen binding s i tes . This 
situation has been cr i t ica l ly reviewed (Faye et a l . , 1987), 
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I C Y 
H OH O 
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2 ^ > OCH^CH2N^J) < ^ ) c h ^ ) o c h 2 C H 2 〈 
Fig. 8 : Structure of some chemical probes used in defining 




S YCK binds to mouse uterine ER with a weak af f in i ty 
comparable to es t r io l (Wang et a l . , 1990). Preliminary 
binding experiments from us (Ho and Kong, unpublished data) 
I . 1, 
had also shown that the binding aff in i ty of YCK with respect 
I to E2 was-well below that of i t s relat ive anti—implantation 
and uterotrophic potencies. Usually a weak estrogen has 
diminished potency because of a lower binding af f in i ty . Given 
at a very high concentration, a weak estrogen would behave 
like a full-spectrum estrogen by fu l l occupancy of ER. 
However, a partial estrogen will bind with difficulty to ER 
and. in a non-competitive manner• Even though at saturation 
binding, AE could not e l i c i t the fu l l spectrum of biological 
responses like E. 
Now that YCK binds weakly to ER but manifests an 
apparently' much more important biological effect , the 
question is raised as to whether YCK binds solely to ER, or 
in addition, to AEBS through which part of 七he biological 
act ivi t ies are expressed. Indeed, using labeled Tam as the 
ligand and ra t liver microsomal fraction as the receptor, YCK 
could effectively displace [
3
H]-Tam binding even in the 
presence of DES. Of course i t may not be fair to compare the 
binding kinetics of YCK, a non-polar compound, with that of 
E2, a polar compound, in an in vitro competitive receptor 
binding system. YCK is probably hydroxylated in the animal 
body and binds to ER with a much higher aff ini ty than noted 
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in Vi t ro , thus accounting for i t s pronounced biological 
act ivi ty . However,七he active enantiomer of a YCK analogue, 
the r(+) -camphor-YCK, which has at least 50% of YCK potency 
(Ho et a l . • 1991) , binds to ER with only 1/10 of the YCK 
af f in i ty (Ho, unpublished data)• This observa七ion lends 
suppor七 to a hypothetical dissociation between ER binding 
af f in i ty and biological potency in YCK and i t s analogues. The 
answer might be sought in the studies of YCK binding to 
alternate binding s i tes (other than ER).工七 i s in this 
perspective 七ha t SAR of YCK was undertaken, in an attempt to 
look for improved analogues with potential application as AE. 
1.5 Multiple and dissociated biological ac t iv i t ies 
AE are cl inically used to neutralise the 
(excessive-) action of E. All known AE's carry a residual 
agonist act ivi ty, but the la t te r is not simply a small 
fraction of the fu l l spectrum estrogenic ac t iv i t ies . AE's are 
useful, in a functional sense, because they could stimulate 
some parts of the fu l l spectrum biological responses in their 
target t issues in which they could be as potent as E. For 
example, both E2 and CI628 (a tripheny 1 ethy 1 ene type AE) could 
e l i c i t 七he same magnitude of response in the stimulation of 
ornithine decarboxylase, an estrogen-sensitive enzyme, but 
with a different time course (Rorke et a l . , 1984) . By the 
same token, while Tam could inhibit growth in MCF-7 cel ls , i t 
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could induce the synthesis of progesterone receptor jus七 l ike 
IS'. • ' . • 产 
H Even though an estrogenic derivative may no 七 
possess anti-estrogenic properties, as a resul七 of minor 
change in the posi七ion of double bond or configuration, i t 
could demonstrate a d i f fe ren t ia l expression of biological 
ac t iv i t i e s . For example, indenestrol, the oxidative 
me七abolite of DES i s found in two forms, indenes七rol—A (IA), 
and indenestrol—B (IB), with a difference in the position of 
the double bond. Bot^ h IA and 工 B have the same binding 
cons 七 an 七 for ER as DES. Although they have weaker 
. . - + • , . 
uterotrophic potency, IA and IB are equipotent in th i s 
respect. When i t c o m e s to glucose—6—phosphate dehydrogenase 
(G-6__PD) , another estrogen-sensitive enzyme, IA i s as potent 
as DES, the parent compound, but IB i s inactive (Korach et 
a l . , 1985)• This example forcefully argues for a dissociation 
• 
of biological responses even in the same molecule once i t 
undergoes metabolic transformation. Here, we could see that 
binding af f in i ty =/= uterotrophic potency =/芽 enzyme 
induction. This brings us immediately to the question : what 
Is the biological prof i le of YCK (since we have only observed 
anti—implantation and uterotrophic act iv i t ies) and in what 




 I . . . . . 
* We have cited above how new chemical probes like 
N,N-DPPE and morpho-BPE could reveal the existence of AEBS. 
Now that we have a novel molecular design for an estrogenic 
compound in forms of YCK, i t could be a very useful tool to 
study the multiple channels of estrogenic action at different 
levels (cellular, genomic, molecular). — 
1.6 A future role for YCK 
YCK is the product of a mission-oriented research 
for non-steroidal an t i - f e r t i l i t y agent. I t could have never 
been invented by total chemical synthesis. The estrogen field 
of study has not yet 七he foresight and imagination to step 
out of the triphenylethylenes. I t could never be discovered 
even by the most exhaustive phytochemical breakdown of 
Murraya originated compounds which have already yielded an 
impressive array of natural products like carbazoles, 
coumarins, terpenoids, alkaloids (Fauvel et a l . • 1978), 
flavones and amides (Kong e t _ a l . , 1987)、 YCK has the 
simplicity of a straightforward biogenesis, the attraction of 
a potent estrogen and the tenacity of a highly conservative 
molecular design with respect to estrogen action. As soon as 
the definite structure was determined in 1983, i t was keenly 
f e l t that the estrogenicity of YCK l ies in the relative 
positive (planarity) of the two indole moieties. Many years 
of hard work that followed led to a handful of structural 
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f analogues designed to limit the spatial arrangement of the 
i . . . . . . . „ .:. 
I 
free indole moiety (K.F. Cheng, personal communication)• It 
！ 
is now fair to conclude that YCK fi ts perfectly well with the 
. ” . ‘ . . : . . . . 卞 . . : 、 
basic design of an estrogen model (Jordan, 1984) (Fig. 9). 
• • 
' -
• . . . . I ‘‘ . - . 
Molecular designs based on the natural steroid ring 
I . • ‘ 
I '• .. . . :‘ 
system, or the synthetic triphenylethylenes have so far 
I dominated the field which culminated in the synthesis of IC工一 
164,384 and Tam, both found useful clinical applications. But 
there is s t i l l room for improvement for fert i l i ty regulating 
agents and breast cancer management drugs• Maybe there: is a 
• . . . ' .
v
 ' • . • .... • • . . . . . . . . . . . : ‘ • • • • . . . ' . _ • . ' . , 
need for a "pure" E that supports female reproductive 
functions but is not carcinogenic (Key and Pike, 1988)• Maybe 
there is a need for an "innocent" E that could help the body 
to screen off estrogenic pollutants without itself causing 
undesirable side effects, thus affording a kind of "chemical 
immunity". Now that we know the dissociation of estrogenic 
actions, there is certainly a need for new chemical probes 
that could reveal the many facetsof pleiotypic responses in 
estrogen action. The answer may be sought , in YCK and i t s 
improved analogues ： hence this SAR study. 
. • . . .、. . . . . . . . . . . ..，、 
Estrogen is a two-edged sword. Women can not 
develop and maintain female functions without estrogen. Even 
.postmenopausal women need the help of estrogen to assist them 
passing smoothly into a sexually neutral state of l i fe . But 
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N.B. (83/91) ： The functional“significance 〇f，the re la t ive 
position of the two indoles was f i r s t noted in '83 but i t was 
only proven in '91 by synthesising analogues with spacing 
groups in.', different 、size (K.F. Cheng, personal 
couffnunication), 
Fig. 9 ： A comparison of the hypothetical ligand receptor 
• model between E and YCK to. describe the structural 
requirements for biological activity in vitro. 
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estrogen is carcinogenic for sensitive target t issues, 
.. 
notably the breast t issues • The use of Tam for advanced 
breast cancer i s indisputable. But even af ter radical 
I 
mastectomy, there is a high recurrence rate of micro-
metastases distant from the primary tumor s i t e s . In th i s 
case, adjuvant therapy with Tam proves also useful. This 
requires long-term treatment. This practice gradually changes 
the strategy of Tam application and breast cancer management. 
Without knowing exactly when would the carcinogen insult 
s tr ike, i t might be useful to cover "high risk" patients with 
Tam as a chemo-suppressant. This brings out the consideration 
for the side effects of Tam and i t s metabolites and the 
risk/benefi t ra t io must be re-evaluated for endocrine 
treatment of pre~menopausal women. Enormous effor ts , namely 
s t a t i s t i ca l analysis of cl inical t r i a l s to study the 
epidemiology of breast cancer and i t s management came up with 
i . . . 
a very positive statement in favour of Tam administration 
(Early Breast Cancer Tr ia l i s t s , Collaborative Group, 1992). ： . - . • , , k • , . 
But a l l 七 h e s e benefits are incremental, although i t i s 
... ‘ .,.., “‘. 
translated into- the survival advantage of thousands of women 
a year, and the beneficial effects could be put in doubt 
again once there are research resul ts . The message i s clear 
： w e need adjuvant therapy and chemo suppress ants. But can we 
have a better drug than Tam ？ With a l l those effor ts thrown 
into the study of Tam in every aspect and every minute 
detai l , can we spare a small fraction of those imposed upon 
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Tam by considering a novel molecular design ？ That could have 
totally allayed the worries and constraints for doctors in 
Tam administration. 
-While eagerly hoping to bring palliation to the 
patients, several important reviews on breast cancer and 
endocrine treatment have recently appeared (Jordan, 1990a, 
Early Breast Cancer Trialists' Collaborative Group, 1992; 
Jordan and Murphy, 1990b) . We wish to expand even more the 
perspectives in this field by bring, in yuehchukene. 
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Chapter Two 
2 Materials and Methods 
^ H • :、 • 
2.1. Chemical Synthesis 
. . . 
2.1.1. Synthesis of Yuehchukene 
I 
The strategy of yuehchukene (1) synthesis involving 
. 
an intermolecular Diels-Alder cyclisation of MBDI is shown in 
Scheme 1. The precursor 3-isoprenylindole (MBDI) was 
synthesised for th is purpose. 
• • ； - ^ ^ H • 
工 n d o l e — 3 — c a r b a l d e h y d e was protected as the N_p— 
toluenesulphony1 derivative.工七 was treated with Grignard 
reagent derived from 3-chloro-2-methylprop-l-ene and final ly 
gave the alcohol af ter appropriate purifica七ioru The alcohol 
was then deprotected and dehydrated in one step to afford the . . ' . . . . 
3~isoprenylindole (MBDI)• Acid—catalysed dimerisa七ion of MBDI 
in the presence of s i l ica gel followed by s i l i ca gel 
chromatography yielded yuehchukene (1) in pure form (Cheng et 
a l . , 1985; Gao et a l . , 1989)• 
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Scheme Reagents : i , NaH, TsCl, THF; i i , 
CH2 = CMeCH2MgCl/ THF； i i i , 3N K〇H/D七OH厂 
iv, CF3COOH, s i l i ca gel, benzene, 60°C. 
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Scheme- 2^ .:: Reagents、r i , acetic: anhydride, sodium、acetate c 
re f lux" 4 hours.,. 
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2.1.2. Substitution of Yuehchukene 
2.1.2.1 Substitution at N-1
1
 and N-5 
Acetylation, succinylation, and methylation of 
YCK gave- the respective N—1
1一substituted derivatives of 
yuehchukeneV namely N-1'-acetyl-YCK. (2)/ N-1'-succinyl-YCK 
(3), and N-l.-methyl-YCK^A). By methylation under more 
vigorous conditions, disubstituted N-1丨，N-5-dimethyl-YCK (5) 
could be obtained (Fig. 10). 
N-1
1
-acetyl-YCK (2) was prepared by refluxing YCK 
for 4 hours with acetic anhydride in the presence of sodium 
acetate, Scheme 2. 
- _ • 
N-1
1
-succinyl-YCK (3) was prepared by treat ing YCK 
• _ • - « 
I with sodium hydride f i r s t in anhydrous THF at 0°C under 
nitrogen and s t i r red for 5 hours. Succinic anhydride was 
added and s t i r red for another 15 hours. Dilute HC1 was added 
to 七 he solution arid af ter appropriate extraction and 




-methy1-YCK (4) was prepared by adding YCK in 
THF dropwise to sodium hydride in anhydrous THF at room 
temperature under nitrogen. The mixture was s t i r red unt i l gas 
ceased to evolve. Methyl iodide was added and s t i r red for 
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(1) R = H , R
1
 = H 
(2) R = H , R
1
 = Ac 
(3) R = H , R' = COCH2CH2COOH 
(4) R = H , R
1
 = Me 她 
(5) R = Me , R' = Me 
⑷ R = OMe , R' = OMe 
H , . 
、 T C i l 1 J 
- 、1 I 
H 
(7) R = Me 
(8) R = OMe 
H 
(9) R = H , R
1
 = H 
(10) R = OH , R ' > H 
(11) R = H , R' = OH 
F i g . io ： Structure of substituted yuehchukene derivatives,* 
their act ivi t ies are presented in Table 1. 
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Scheme 4. Reagents : I , NaH, THF, Mel, r . t . 
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another 0.5 hour. The whole was poured into ice water then 
I extracted with ether. Chromatography of the residue on s i l i ca 




 ,N-5-dimethyl-YCK (5) was prepared similarly as 
compound (4) except that potassium hydride (35% in oi l 
suspension) was used. Excessive methyl iodide was added af ter 
hydrogen gas ceased to evolve. After s t i r r ing the mixture for 
0.5 hour, water was added and then extracted with ether. 
Removal of solvent afforded compound ( 5 ) , Scheme 5 . 
The N-1,,N-5-dimethoxy-YCK (6) was prepared using 
a procedure analogous to the biomimetic synthesis of YCK by 
employing N_me七hoxy-indole as the start ing material. Thus N-
methoxy—indole (Acheson et a l . , 1984) was converted to i t s 
aldehyde by Vilsmeier (Smith, 1954) reaction. In a typical 
Grignard reaction, treatment of the aldehyde with 2-
methylpro-2-enyl magnesiuiri chloride in THF gave the alcohol 
which upon dehydration with mesyl chloride in triethylamihe 
gave the diene. The crude diene, without purification, was 
subjected to acid-catalysed dimerisation in the presence of 
s i l ica gel and N-l
!
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Scheme 5. Reagents : i , KH, THF, Mel, r . t . 
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Scheme 6. Reagents : i , P0C13/ DMF; i i , CH2 = CMeC^MgCl, THF| 
i i i , Et3N, MeS02Cl; iv, MeONa, MeOH; v, s i l ica gel, benzene, 
60°C. “ 
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Scheme 7. Reagents : i； P0C13/ DMF; i i , NaH, TsCl, DMF; i i i , 
CH2 = CMeCH2MgCl, THF; iv, 3N KOH/EtOH； v, CF3COOH, silica gel, 
benzene, 60°C * 
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Scheme 8. Reagents : i , P0C13, DMF,. i i , NaH, TsCl, DMF; i i i , 
CH2 = CMeCH2MgCl, THF； iv, 3N KOH/E七OH; v, CFfOOH, s i l i ca gel, 
benzene, 60°C. 
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were prepared from 5-methyl-indole and 5-methoxy-indole 
respectively, Scheme 7 , Scheme 8. However, in these cases f an 
extra step to introduce a N—七osyl protecting group was 
necessary before the Grignard reaction. Removal of the N-
t o s y l protecting group occurred concomitantly with 
dehydration by treating 七 h e alcohol with 3 N ethanolic 
potassium hydroxide. 
2.1.2.3 Saturation of C9_C10 Double Bond 
Saturation of C9-C10 double bond was achieved by 
catalytic hydrogenation of YCK over Adam's catalyst at room 
teiaperature under 40 psi pressure for 40 hours to give the 
9,10-dihydro-YCK (9) • Hydroxylation of C9_C10 double bond with 
osmium tetroxide afforded 9 f10-dihydroxy-YCK (10)‘ Scheme 10. 
2•1•2•4 Aromatic Hydroxylation 
The, 2,5
1
-dihydroxy-9,10-dihydro-YCK (11) was 
prepared from 2 , 5 丨 一 d i i n e t h o x y — Y C K (8) by firs七 saturating the 
C9_C10 double bond by catalytic hydrogenation, followed by 
cleaving the methyl ether with ethane七hiol in aluminium ( 工 工 I ) 
chloride and aqueous hydrochloric acid (Node et a l . , 1980). 
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( 9 ) 
Scheme 9. Reagents ： i , Adam's catalyst, benzene, 40 psi, 
r . t . , 40 hours• 
O H 丨 
� 丄 。 ^ 
_ . 書 
" H 
(10) 
Scheme 10, Reagents : i, pyridine, anhydrous ether, r5°C; i i , 
0s04, 2 hours； i i i , 10% mannitol, CH2C12/ NaOH, 0°C, overnight. 
H H H H 1 H y 
i ‘ ii 
(8) > H 7! H / \ ~ H 
H H 
(11) 
Scheme 11. Reagents : i , Adam's catalyst, benzene, 40 psi, 
r . t . , 40 hours； i i , EtSH, A1C13/ 0°C; i i i , HC1. 
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Attempts to demethylate 2,5
1
-dimethoxy-YCK (8) were not 
successful unless the C9-C10 double bond was saturated, Scheme 
11. 
2.1.2.5 - Synthesis of Benzofuran-3-HMBI 
Benzofuran""3-HMBI (Cpd 33) was made through a 
typical Grignard reaction by treating benzofuran-3-
carboxaldehyde with 2-methylpro~2-enyl magnesium chloride in 
THF. Benzofuran-3-carboxaldehyde was prepared by l i tera ture 
procedure (Shafiee et a l . , 1978)• 
2.1.3 Stereo-selective Synthesis of R( + )- and S(-)-
Camphor-yuehchukene 
R(+)-Camphor-yuehchukene (12) was prepared from 
commercially available enan七iomerically pure (1R)-(+)-
camphor, [a]D ^ +44.1° (Aldrich, 99% pure). Likewise, (S)— 
(-)-Camphor-yuehchukene (13) was prepared from (IS)-(-)-
camphor, [a]D = 一 4 1 。 (Aldrich, 95% pure) • The geneiral routes 
are shown in Scheme 12, Scheme 13 respectively. 
The strategic approach required the synthesis of 
the tetracyclic ketone as the key intermediate step (Cheng et 
al . , 1988) which was deviated from the general synthetic 




synthetic routes led to tetracyclic ketone involved the 
reaction between vinyllithium derivative with Indole-2-
carboxaldehyde and followed by Nazarov cyclisa七ion of the 
divinyl ketone. Reduction of the ketone and followed by 
substitution of the appropriate indolyl moiety provided a . 
handful of YCK analogues (Cheng et a l . , 1991). Likewise, 
enantiomerically pure ketone was prepared by employing either 
(1R) -(+)-camphor or (IS)- (-)-camphor as the star t ing material 
to generate the respective vinyllithium derivatives and hence 
obtained the enantiomerically pure R(+)-camphor-YCK (12) and 
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Scheme 12. Reagents : i , Triisopropylphenylsulphonyl-
hydrazide, HC1, MeCN; i i , Bu
l
Li, THF, —70 ”^ 0°C; i i i , Mn02/ 
r . t . , 12 hoursr iv, BF3.Et20, toluene, reflux, 15 hours; v, 
DIBAH, THF, 0°C; vi, BFs.Et^ O, indole, THF, 0°C;. vii,、BF3.Et20, 
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Scheme 13. Reagents : i , Triisopropylphenylsulphonyl-
hydrazide, HCL/ MeCN; i i , Bu
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Melting points were measured on a Reicher七 Kofl@S，_ 
hot-stage apparatus and are uncorrected, NMR spectra were 
recorded on a Jeol FX-90Q spectrometer in deuteriochloroform 
unless otherwise stated with tetramethyl-silane as internal 
standard. Mass spectra were recorded on a Hitachi RMS—4 and 
VG 70-7OF high resolution mass spectrometers. Thin layer 
chromatography was performed using Merck pre-coated s i l i ca 
gel F-254 plates (thickness 0.25 mm) . Flash chromatography 
used Kieselgel 60 (Herck) as the stationary phase (S t i l l , 
1978). Analytical HPLC was performed on Beckman Model 331 
HPLC System with a UV detector. Semi-purification was 
performed on Lobar Columns (Merck). Preparative HPLC was 
performed on Waters PrepLC/System 50OA using Prepak-500/C18 
reverse phase column. Radioactivity of [
3
H] -estradiol or [
3
H]-
tamoxifen was measured by a Beckman Liquid Scint i l lat ion 
Counter (LS1801)• 
2.2. Bioassay 
Animal supply -. ’ 
Sprague-Dawley ra t s were random-bred and fed with 
Purina rodent chow and water ad l i b i t u m in an air-conditioned 




1 i • ：. ‘ 
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1-
was maintained throughout the year- Mated rats were numbered 
and assigned to experimental groups sequentially. 
I . 
I 
2 2 1 Anti-implantation Activity 
I : • 
Eight week-old female Sprague—Dawley rats , 200-220 
I 
g, Were supplied on the morning when evidence of mating was 
I indicated by the presence of post-coital plug. This was 
designated as day 1 of pregnancy (P^) • The animals were then 
dosed orally in the morning with 1 ml of drug solution or 
v e h i c l e from PD M f or otherwise assigned. They were autopsied 
on PD8. The number of pregnant a n i m a l s was recorded. The uteri 
were removed, trimmed and photographed, then preserved in 
Bouin fixative. The absence of implantation s i tes was an 
indication of anti-Implantation activity. All analogues were 
dosed to achieve an ^all or none' end point. Each group of 
animal contained at least 5 ra ts . Drug at a l l control groups 
.‘:’ --
were vehicle only at 1 ml per 250g body weight. 
I -
I, ® 




Female Sprague Dawley rats , 21 - 23 day-old, were ’ “ 
ovariectomised and were allowed to recover for 3-7 days. 
After that they were dosed orally twice daily for 3 days with 
0.2 ml of drug solution for each dose. A vaginal smear was 





f noted. During autopsy the uterine horns were excised, trimmed 
f r e e of fat ty t issue, blotted dry and weighed in a precision 
balance. The increase in uterine weight was a measure of 
uterotrophic response to estrogenic activity. Each group of 
J a n ima l contained 6-8 ra ts . Drug at a l l control groups were 
aiven vehicle only. 
I 
I / 
I . ...,. 
2.2.3 Blue Test 
p- “ • • 
• . 
The Blue Test (Psychoyos, 1963) served to determine 
the time of implantation. In th is protocol, ra ts were dosed 
d u r i n g Pregnancy Day 1-4 (PDM) . On the afternoon of PD4/ a 
ra t was injected intravenously with 0.2 ml of 3% pontamine 
I • 
sky blue 6BX in physiological saline. After 15 minutes, the 
r a t was laparotomised under ether anaesthesia and the blue 
spots visible from the serosal side of the uterine wall were 
counted. A blue spot indicated penetration of the vi ta l stain 
due to invasion of the maternal tissue by blastocysts. The 
number of implantation si tes in both uterine horns were 
counted, usually there were 6-7 blue spots spreading at equal 
distance in each horn " But even the presence of 1 blue spot 
was considered positive, result indicating the f i r s t time 
point in implantation. There were 5 rats in each group and 
the whole experiment from one group lasted 60-90 minutes. 
Four more groups were timed to be autopsied on the morning 
and afternoon of PD5, and again PD6. 17a-ethynylestradiol was 
： - . : . . . . ‘ . - . . . • . ‘.: "r / . . . “ 
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p 
I used as positive control. 
D r u g s were formulated in ethanol : benzyl benzoate 
• olive oil (l:1:8 v/v) and delivered by intubation through 




2.2.4 Binding Assays 
I , • • 
J-
I 
Immature female Sprague-Dawley rats, 20 - 24 day-
old, were killed by cervical dislocation and uter i were 
rapidly r e m o v e d , trimmed free of fatty tissue, blotted and 
• 
weighed• 
1 ^H ‘ ^H 
2.2.4.1 Uterine Cytosolic Estrogen Receptor Binding Assay 
Uterine cytosolic estrogen receptor binding was 
assayed according to the instructions of a Rianen [
3
H]> 
Estrogen Receptor Assay Kit (Du Pont Co.). To recapitulate in 
essence, immature female Sprague-Dawley rats uteri were 
pooled and homogenised (50 mg/ml) in ice-cold Tris-buffer, PH 
7.4. The homogenate was centrifuged at 35000 x g for 1 hour 
at 4°C. Protein concentration was adjusted to 2 mg/ml. 3 nM 
[3H3-E, was used to saturate the binding on estrogen receptor 
without YCK. A b i n d i n g displacement curve with increasing 
concentrations of YCK was thus obtained. In another 
I experiment, pretreatment of the cytosolic receptor with YGK 
was performed by incubating the receptor preparation with 
54 
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various concentrations of YCK under the same conditions. 
•s) . • 
After 20 hours, 3nM [
3
H]-E2 was added and incubated for 
誦 
another 20 hours. Then 300 Ml dex七ran—coated charcoal 
I • • 
suspension was added and incubated for 15 minutes. The 
j I ^ l^M 
suspension was centrifuged at 1500 x g for 15 minutes. 
Superna七ants were counted for radioactivity in 2 ml 
sc in t i l la t ion cock七ail (4g PPO, 0.2 g POPOP, 332.5 ml Triton 
X-100 and 667.5 ml toluene (per l i t r e ) ) . 
I H ; •, . 
2.2.4.2 Liver microsomal fraction anti-estrogen receptor 
. - ； • , • V 、 . ,-=..'、.,-
binding ass^y 
1 ^^H H^ 
[N-methyl-
3
H]Tamoxifen (82.5 Ci/mmole) was obtained 
from Amersham 工 i r t e r n a t i o n a l and stored in ethanol a七 一2 0oC 
protected-from light. Tamoxifen, diethylst i lbestrol and other 
chemicals were obtained from Sigma Chemical Co. 
I 
I 
Liver lobes were removed from 200 — 250 g female 
I 
Sprague-Dawley rats af ter ether anaesthesia and homogenized 
• 
in 12 volumes of ice-cold buffer (10 mM Tris/HCl, 1.5 mM 
disodium EDTA, 20 mM sodium molybdate, 10% glycerol, pH 7,5) • 
The homogenate was centrifuged at 20000 x g . for 30 mm and ] -
the supernatant was stored at -70°C (Hwang 1986). 
] 
. . , . . 、 . . ； . . . . , . / . . .. . . — • . 
I 
The supernatant prepared from rat liver was diluted 






incubated with approximately 2 nM [
3
H]-tamoxifen (10^1) in the 
I ' . . . . . . ^^  
absence or presence of various competing ligands (Tam or YCK 
dissolved in 10 )il of ethanol) in a f inal volume of 520 pi. 
All assay tubes contained 1 jaM diethyls t i lbestrol to 
eliminate binding of [
3
H]-Tam to estrogen receptors. After 
incubation for 16 hours at 4°C, 0,25 ml dex 七 ran—coated 
charcoal suspension (10 mM Tris/HGl, 10% glycerol/ 0.25% 
Noirit A charcoal, 0. 025% dextran T70, pH 7.5 at 4。C) was added 
and fur七her incubated for 15 minutes. Then the suspension was 
centrifuged at 1500 x g for 15 minutes. Superna七ants were 
counted for radioactivity in 4 ml of scirrti l lation cocktail 
(4 g ppo, 0.2 g POPOP, 332.5 ml Triton X-100 and 667.5 ml 
toluene (per l i t r e ) ) . Under the present conditions of binding 
assay, the microsomal preparation could bind more than half 
of 七 h e to ta l counts, while only 14.5 % of to ta l counts was 
non-specific binding. In the presence of DES, 96 % of 
specific binding to AEBS remained. Cold Tam displacement of 
labeled ligand was tested between 0.3 nM to 1.8 YCK up to 
3 fiK could not displace [
3
H]-Tam binding. 
2.2.5 Enzyme Activities 
2.2.5.1 Ornithine Decarboxylase Activity Assay 
Immature female Sprague-Dawley ra ts , 20 - 24 day-
old, were injec七ed with tes t samples subcutaneously in 0.2 ml 
56 
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of olive oil / 10% ethanol a七 op七imal dose recommended by 
l i terature and sacrificed after 20 hours. Rats were killed by 
cervical dislocation and uteri were rapidly removed, trimmed 





C]ornithine (56 mCi/mmole) was purchased from 
j Amersham I n t e r n a t i o n a l . 1 7 a - e t hyny l e s t r a d i o l , 
I . ； 
diethylstilbestrol and tamoxifen were obtained from Sigma 
Chemical Co. 
Uteri were homogenized at 50 mg/ml in ice-cold 
buffer (50 inM Tris f 0.1 mM EDTA, 0.05- mM pyridoxal-5-
| phosphate, 5 mM dithiothreitol； pH 7.4) and the homogenate 
was centrifuged at 37000 x g in a Sorvall centrifuge for 3 0 
min at 4°C. The supernatant was collected for assay. The 
reaction mixture contained 1.0 - 2.0 mg uterine supernatant 
protein and 40 jjM L-[1-14C]ornithine in the Tris-pyridoxal 
phosphate-dithiothreitol buffer. Incubations were carried out 
in 15 ml home-made glass bottles and sealed with-^a rubber 
stopper. Each bottle contained a polyethylene counting vial . 
The
 14
C02 released was absorbed in 0.25 ml laethylbenzethonium 
hydroxide contained in the counting vial . The bottles were 
incubated at 37°C for 1 hour at which time 1 ml of 10% 
trichloroacetic acid was injected through the rubber septum 
directly into the reaction mixture. The bottles were then 
57 
incubated for a further 1 hour. The counting vials were then 
counted in 4 ml of toluene scint i l la t ion cocktail. Protein 
concentrations were determined by Biorad protein assay 
I . .  % . 's ；： 
solution. Enzyme preparations from different groups were 
adjusted to the same protein concentration prior to assay 
(Korach et a l . , 1979). 
I ^  - ^ 
《 . • -
2.2.5.2 Glucose-6-phosphate Dehydrogenase Activity Assay 
Immatmre female Sprague-Dawley rats , 20 - 24 day-
old, were injected with tes t samples subcutaneously in 0.2 ml 
of olive oi l / 10% ethanol at optimal dose recommended by 
l i terature and sacrificed after 2 0 hours. Rats were killed by 
cervical dislocation and uteri were rapidly removed, trimmed 
free of fat ty t issue, blotted dry and weighed in a precision 
balance. 
Uteri were homogenised at 50 mg/ml in ice-cold TEGM 
buffer (10 mM Tris, 1.5 inM disodium EDTA, 10% glycerol, 3 mM 
magnesium chloride, pH 8.0). Enzymatic activity of glucose-6-
phosphate dehydrogenase was assayed by Sigma Diagnostic (G-6-
PDH) ki t (Sigma Chemical Co.). 
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I 2.2.6 Cell Culture 
2.2.6.1 MCF-7 cell line 
H
1
 … ， . 
-The MCF-7 cell line used in these studies was ！ . • .• •‘ . • 一 
obtained from America Type Culture Collection (Rockville, 
MO). Cell stocks were cultured in RPMI 1640 medium (Sigma 
I Chemical Co., St. Louis, MO) / supplemented with 10 % (v/v) 
fe ta l bovine serum, sodium pyruvate (1 mM; Sigma Chemical 
Co., St. Louis, MO)f bovine insulin (10 Mg/ml； Sigma Chemical 
Co. , St. Louis, MO) , penicil l in (100 units/ml) and 
streptomycin (100 fig/ml) . All tissue culture reagents were 
obtained from Grand Island Biological Co., Grand Island, NY, 
unless otherwise stated. Cell stocks were kept in 150 cm
2 
flask (Corning, Park Ridge,工L) in a humidified atmosphere of 
95 % air/5 % C02, at 37°C. Cells were removed from flasks with. 
0.25 % 七 r y p s i n / E D T A solution for passage. All experiments 
were conducted on cells in continuous passage between 
passages 152 and 156 (Eckert and Katzenellenbogen, 1982). 
2.2.6.2 Growth-response, studies , 
For growth-response studies with the MCF-7 cell 
lines, approximately 1.4 x 10
4
 cells were plated directly into 
24 - well plate (Corning, Park Ridge,工L) and incubated for 
59 • 
t 
•' I . 
• . '" . . . . .. / , ' -1 . V • . ； . ； . ‘ • • .“ ，. . . . 
： ： . 。 
24 hr with phenol red indicator-containing medium with 5 省 
d e x t r a n - c o a t e d charcoal-stripped calf serum. On the following 
. - • . . ^ 
day, the medium was changed to phenol red indicator-free 
medium with the same concentration of serum/ and subsequent 
changes were made for 2 more days. Twenty four hours la ter , 
medium con七aining 七 e s t e d compounds was added and changed 
daily as the cells were allowed to grow for 5 days. On day 5, 
cel ls were harvested for DNA assays (Leake et a l . , 1987; 
Murphy et a l . , 1990). Briefly speaking, the cel ls were pulsed 
I with [
3
H]-thymidine (5 /xCi/itil) only for the f inal 2 hours of 
incubation and then washed thoroughly with ice-cold phosphate 
buffer saline (PBS). After addition of 1 ml of ice-cold 10 % 
trichloroacetic acid (TCA) to each well,七he cel ls were 
sonicated for 1 minute or unti l over 80 % of the cel ls were 
broken (checked in a phase-contrasted microscope). The 
precipitate was collected on a Whatman GF/C f i l t e r and washed 
with 10 ml of ice-cold 10 % TCA. The f i l t e r was placed into 
七 h e sc int i l la t ion insert vials . After drying at 100°C for 15 
minutes, 4 ml Tri七on/toluene scin七illant was added. The 
radioactivity was measured by a Beckman Liquid Scintil lation 
Counter (LS1901) • 
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Exhibit 工 : P i c t u r e s showing the habitus of Murraya 








Exhibit 工工•• A sample of yuehchukene (MP 78 C2) from home-
grown root extract obtained by purification m 丄 
column. This sample was proven active and i t s spectral clara 
confirmed the structure of yuehchukene. I t was stored in 
nitrogen at -70°C since Sept. 1982 with no visible change m 
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Exhibit 工 工 工 ： P i c t u r e s above show the implantation s i t e s of 
female ra t u ter i on PD3 from ra ts treated with yuehchukene 
(lower photo) or from control group (upper pho七o)• 
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Exhibit IV : Picture shows 七he implanta七ion s i tes as dis t inct 
blue spots in the control (upper) group. Uteri from YCK— 
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Exhibit V : Picture was taken 20 hours af ter drug 
administration.工七 shows the uterotrophic effect of estrogen 
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Chapter Three 
Results 
3•1 - Chemical synthesis 
3 . 1 . 1 Yuehchukene (Cpd 1) 
Yuehchukene (1) was synthesised according to Scheme 
1.工七 was obtained 98 % pure from preparative HPLC as a l ight 
yellow powder and the structure was confirmed by the 
following spectral data. 
C26H26N2 (M
+
 366.2097, calc. 366.2096) ； [a]D = 0°; IR 
(KBr) 3400, 2955, 2866, 1618, 1548, 1454, 737 cm'
1； m/z(70eV) 
366 (M+) (100%), 364(5), 269(12), 267(6), 257(24), 234(36), 
1 3 0 ( 3 2 ) ( 3 6 0 MHZ) 0 . 8 6 (3H7s) , 1 . 1 0 (3H,s), 1 . 6 6 (3H,br.s, 
9-Me), 1.63, 2.28 (2H,ABg, 2x8-H), 3.15 (lH,dd,J8.5, 7Hz,6a-
H), 4.02 (lHAmr10a-H) ； 4.56 (1H,d,J8•5 Hz , 6 - H ) / 5•70 (1H, 
br-s , 10-H), 6 . 9 8 - 7 . 1 2 (5H,m), 7.35, 7.43, 7.58 (3H, 3xd), 
7.58,8.0 (2H, br .s , replaceable by D20)• (90.56 MHz) 
quartets； 2 3 . 9 1 , 28.83, 28.95; t r i p l e t s 41.03, (C_8); 
doublets 37.54, 38.28 (G-10a# C-6), 60.80 (C-6a), 111.14, 





, C-10), 122.08, 122.16, 122.90 (C-3, C_ 
2», c-6')； Singlets 33.41 (C-7), 118.50 (C-3')/ 120.46 (C-
10b), 124.23, 126.76 (C-3a、 C-lOc), 130.13, 136.47 (C-4a, C-
66 
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7a”，140.22, 145.09 (C-5a, C-9) • 
3.1.2 Substitution of Yuehchukene 
3.1.2.1 •Substitution at N-1
1
 and N-5 
N—1»—acetyl一YCK (Cpd 2) was obtained according to 
Scheme 2. N-1
1
-acety 1-YCK (2) thus obtained was a brown 
residue which upon s i l i ca gel purification yielded a 
colourless solid (21 mg, 79%) / itip.=243°C (from absolute 
ethanol) 知 ( 9 0 Mpz) 0 • 89 (3H, s , 7-Me) , 1 • 12 (3H, s, 7—Me), 
1.65(lH,d,J=17HZ,8-H), 1.66(3H,S,9-Me), 2.25 (lH,d,J=17Hz,8-
H) f 2.56(3H,s,COMe) , 3.17(lH,m,6a-H) , 4 . 01 (lH,iti, 6-H), 
4.53(lH,d/J=8Hz/10a-H) , 5.69(1H,br.s,10-H) , 7.51(1H,br.s, 
exchangeable with D20, NH), 7.59-7.09(8H,m,ArH), and 
8.44(lH,d/J=6Hz/7«-H)； m/z 408(M+). 
• ‘ •..« . 
N-1
1
-succinyl-YCK (Cpd 3) was obtained according to 
Scheme 3. N-1'-succinyl-YCK (3)七hus obtained was a dark 
brown residue which upon s i l ica gel purification afforded a 
yellow solid (25' irig, 20%) , mp=146-148°C (from petroleum 
ether) , (90 MHz) 0.84 (3H,s) , 1.07(3H,s) , 1. 64 (3H, s) , 3 • 28-
2 . 7 ( 5 H , m ) , 4 . 0 ( l H , m ) ； 4 . 5 ( l H r d ) , 5 • 6 4 ( 1 H , b r • s ) , 1 乃-
7.0(9H,m), 8.32(lH,d,J=9HZ)；m/z 466 (M+)• 
N-1
1
-methyl-YCK (Cpd 4) was obtained according to 
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. , t 
I 
: .,,. '‘ . ’ r、 - ， - V t \ • .‘. ‘ “ . / . j - ’、 , , ' , ^ - '•‘. 
i Scheme 4. N-l
1
-methyl-YCK (4) was a viscous dark brown 
residue which was further purified by s i l ica gel 
chromatography and yielded a light brown powder (8 mg, 24%), 
(found: M
+
, 380.2257. C27H28N2 requires M, 380.2246) , mp=127-
129°C (from petroleum ether) ； (90 MHz) 0.84 (3H, s f 7-Me), 
I 1 . 0 8 ( 3 H / s f 7 - M e ) ； 1•65(3H,s,9-Me), 2 . 1 7 ( 1 H , b r . s , 8 - H ) , 
2 . 3 5 ( l H / b r . s f 8 - H ) , 3 • 1 0 ( 1 H , d d , J = 7 • 5 , 8 • 3 H z , 6 a - H ) , 
J 
S.eSCSH^S^N'-Me), 3.97(1^^,10¾^)^ 4 • 50 (1H, d, J==8 • 3Hz, 6-H), 
5 . 68 (1H, br. s , 10-H) , 6 . 80-7 . 59 (lOH l^ti, Ar-H). 
I • I • 
N~l » ^-S-dimethyl-YCK (Cpd 5) was obtained 
according to Scheme 5. N-l
1
,N-5-dimethyl-YCK (5) thus 
obtained was a viscous dark brown residue which was semi-
* ' ' ' 
purified by si l ica gel chromatography. The..light brown 
• . . ... ", 
residue obtained was further purified by using Lobar Column 
(Si60, 40-63 jititi) ； eluting with e t h e r - l i g h t petroleum 4/7 
afforded a pale yellow； solid (93 mg, 47%)(found: M+, 
394.2412. C28H30N2 requires M, 394.2407)； mp=207-209°C (from 
. . . 
pe t ro l eum e t h e r ) ； <SH(90 MHz) 0 • 83 (3H, s , 7-Me) ' 1. 08 (3H, s , 7-Me), 
1 . 6 3 ( l H / d ; j = 7 . 6 6 H z , 8 - H ) , 1 . 65 ( 3 H , b r . s , 9 - M e ) , 
I 2.22(lH/d,J=7.66Hz,8-H) , 3 . 0 4 ( l H , m , 6 a - H ) , 3 • 1 0 ( 3 H , s , N - M e ) , 





,N—5—dime七hoxy-YCK (Cpd 6) was synthesised 
68 
I 
according to Scheme 6. N - l
1
,N-5 -d imethoxy-YCK (6) thus 
obtained was a dark brown viscous oi l which upon purification 
by a Lobar s i l ica gel column (Si60, 40 - 63 /m) eluted with 
ether-l ight petroleum 4/7 yielded a pale yellow solid (110 
mg/ 11%) (found: M
+
, 426.2301. C28H30N2O2 requires M, 426.2305), 
mp=146-147°C; 5 H ( 9 0 M H z ) 0 • 8 4 ( 3 H , s , 7 - M e ) 、 1 . 1 0 ( 3 H , s , 7 - M e ) , 
I ^H 
1.64(3H,9-Me), 3•12(1H,dd,J=7•7Hz,6a-H), 3•27(3H,s,OMe) t 
I 
3.81(lH,m,10a-H), 4.03(lHrs,OMe), 4•65(lH,d,J=7Hz,6-H)• 
I 
5.69(lH#m,10-H), 7•01-7•58(9H,m,Ar-H)• 
^ H I .: ： • H ^ ^ ^ H 
3.1.2.2 Substitution at C2 and C5 
• ‘ . . : 
2,5
1
-dimethyl-YCK (Cpd 7) was synthesised as shown 
in scheme 7. 2, 5
 1
 -dimethyl-YCK (7) thus obtained was a dark 
一.厂 . 
brown viscous oi l which was semi-purified by s i l ica gel 
chromatography and yielded a light brown residue. The residue 
was subjected to Lobar Column (Si60, 40 - 63 严 ) e l u t e d with 
ether-light petroleum 3/7 which afforded a white powder (80 
mg, 8%) , mp=129-131°C (from petroleum ether) (found: M
+
, 
394.2404. C28H30N2 requires M, 394.2402) ； 5H(250 MHz) 
0.84(3H/s/7~Me)./ 1 • 11 (3IT,s,7—Me) , 1 • 57 (1H,d, J=16Hz, 8 —H), 
1.63(3H,9-Me), 2 . 23 ( 1H ,d , J=16Hz ,8 -H) , 2 . 3 8 ( 3H r S , 2 -Me ) , 
2.43(311,5,-1^), 3.11(^^(1^=8 .1/ 7Hz , 6a-H) , 3 • 98 (1H, m, 10a-
H) , 4.44(1H,d,J=8.1Hz,6-H), 5•64(lH,m,br•s,10-H), 6.85-




to Scheme 8. 2 , 5 •-dimethoxy-YCK (8) thus obtained was a brown 
I：?'"、.？:. 〜 : " ! ..‘；. . ‘ ‘ 、 , , : . .. . . . .」. 
I 
residue which upon purification by Lobar Column (Si60, 40 一 
60 juiti) eluted with ether-light petroleum 4/7 afforded a 
yellow solid (150 mg, 9%) , mp=118-119
0
C (from petroleum ether) 
(found: M
+
, 426.2311. C28H30N2O2 requires M, 426.2305) ； SH(90 
MHz, C6D6) 0.94 (3H/s,7-Me) , 1 • 15 ( 3 H , s , 7-Me)' 
l.SeflHVd^^Hz^S-H) , l-65(3H,s,9 一 Me) , 3 .16 (1H71A J=7 . 9Hz , 6a-
H) , 3.39(3H ,s,OMe) , 3 . 59 (3H, s, OMe) , 4 .10 (lH^, lOa-H), 
4.50(lH,d,J=7,9Hz,6-H), 5 .85(1H,br•s,10_H) and 6.46-
• ^H • • 
7.23(9H,m,Ar-H)• 
. . 、 . . 
‘
1




3.1.2.3 Saturation of C9-C10 Double Bond 
‘9,10~dihydro-YCK (Cpd 9) was synthesised according 
to Scheme 9. 9,10-dihydro-YCK (9) thus obtained after 
hydrogenation was fi l tered through celi te to remove platinum 
black. Removal of soIveri七 afforded the hydrogena七ed product 
(9) as a brown oil (60 mg, 75%) (found： M+, 368.2247. C26H28N2 
requires M, 368.2251)； 6H(90 MHz) 0•70(3H,s,7_Me), 
0 • 8 1 ( 3 H , d,, J=6 • 12 Hz ,,9-Me) , 0 • 97 ( 3H , s , 7 -Me) , 
2.93 (1H, (1(1^=6.12,10. 06 Hz, 6a-H), 3 • 3 6 (1H, d, J=10 • 06Hz , lOa-H), 





9,10-dihydroxy-YCK (Cpd 10) was synthesised 
I ' according to Scheme 10. 9,10-dihydroxy-YCK (10) thus obtained 
was a brown residue which upon si l ica gel purification with 
ether-light petroleum 4/7 afforded a yellow solid (41 mg, 
] 15%) , (found: M
+
, 400.2146. C26H28N202 requires M, 400.2144); 
mp=159-161°C (from hexane)； Sn(90 MHz) 0.80(3H,s,7-Me), 
1.14(3H,s,7-Me) , 1. 3 6 (3H, 9-Me) , 1.55(21^,2-,8-11), 
1• 7 3 ( 1 H , b r . s , e x c h a n g e a b l e w i t h D20, OH), 
1• 9 4 ( 1 H , b r , s , e x c h a n g e a b l e w i t h D20, OH), 
2.97(lH,d,J=10.28Hz,6-H)/ 3•21(1H,dd,J=10•06, 6•56Hz,10a-H), 
3,62(^^(1^=10.28, e.^SHz^a-H) , 4 • 31 (1H, d, J=10 • 06Hz, 10« 
H)and 6•42-7•86(llH,m,Ar-H)• 
. . . '• . . “ 
. 
3.1.2.4 Aromatic Hydroxylation 
2 , 5
f
- d i h y d r o x y - 9 , 1 0 - d i h y d r o - Y C K ( C p d 1 1 ) w a s 
synthesised as shown in Scheme 11. 2,5'-dihydroxy-9,10-
dihydro-YCK (11) thus obtained was a light brown residue 
r which was purified by si l ica gel chromatography to yield a 
white solid (130 mg, 20%) (found: M
+
, 400.2142. C26H28N202 
requires M, 400.2144)；mp=13 2-13 4°C (from petroleum ether); 
( S h ( 9 0 M H Z ) 0 . 8 5 ( 3 H , s , : 7 - M e ) , 0 . 9 4 ( 3 H , d , J = 6 . 1 3 H z , 9 - M e ) , 
l .OOpH^sJ-Me) , 1.42-2 . 25 (4H,m/ 8- and 10-H2), 
2.98(11^(^=3.5, 9.6Hz, 6a-H) , 3 • 3 0 (1H, dd, J=3 • 5 , 11.6Hz, 
10a-H), 3 .74 ( lH /br.s / OH), 3 . 9 5 ( 1 H , b r . s , OH), 
4 . 2 2 ( lH , d , J=9 . 6Hz / 6—H), 6•22(1H,br•s,2
f
_H) and 6,43— 
71 
, < I 
7.64(8H,m,NH and Ar-H)• 
3.1.3 Stereo-selective Synthesis of R(+)- and S(_) — 
camphor-YCK 
R(+)-camphor-YCK (Cpd 12) was synthesised according 
to Scheme 12. R(+)-camphor-YCK (12) thus obtained showed [a]D • «々  . •‘ 
=+40.5° while S(-)-camphor-YCK (Cpd 13) was synthesised as 
shown in Scheme 13. S (-) -camphor-YCK thus obtained showed [a] D 
=-40.8° (Cheng et a l . , 1991), 
3 . 2 Bioassay 
3.2.1 Anti-implantation Activity 
YCK (1) was 100% active at 2.5 mg/kg, dosing PDM. 
At this dose level, i t was equally active by dosing on PD2 
only. Pure YCK (> 95%) haa a minimum effective dose of 1.2 5 
mg/kg, bu七 in blue 七e s t experiments, i t could be as low as 
0.62 mg/kg (vide infra)• 17a_EE2 was used as a positive 
control. I t was 100 % active at 0.12 mg/kg. Although a l l YCK 
derivatives tested were at least > 85% pure as judged by HPLC 
profiles, their bioavailability may differ . Thus the optimal 
effective dose (O.E.D.) of YCK was set at 2. 5mg/kg, dosing 
PDM/ for the purpose of comparing 七he relative potencies of 
72 
I different derivatives. The dose response curves of EE2 and YCK 
• .-. l . 
are shown in Fig. 11. 
• •II I 丨 • 
N-1 *-acetyl-YCK (2) was readily crystal l izable but 
I _+ 一 .. . 




 -succinyl-YCK (3) was no七 active at a l l at O.E.D. 
‘ . . • 
level. This derivative was water soluble at 1.2 mg/ml•工七s 
water solubil i ty should not affect i t s act ivi ty as YCK 
formulated in a fine suspension in 5% gelatin water had the 
same act ivi ty as YCK formulated in oi l (Fig. 10)• 
N-l
1
- methylation of the free Indole moiety in YCK 
H 
permitted 七 h e methylated derivative ( 4 ) to retain 30% of i t s 
potency. I t was active at 3 x O.E.D. However, methylation of 
七 he ni七rogen a 七 om of both indoles (5) to ta l ly abolished 
act ivi ty even at 6 x O.E.D. By the same token, , methoxylation 
Of 七 he nitrogen atom in both indoles ( 6 ) also abolished 
act ivi ty at 3 x O.E.D. See Table 1 (p. 77) and Fig. 10 (p. 
39) • 
. ' 、 〜 ‘ . . . 
73 
•识：， ， ‘ I 
•雾‘:. ’ 
•囊二),:.:“、:);., / ? ’ . : : . • . ； ' ： . . 
f 
‘ . 
^H y ^ H -‘ 
I ^H . ^H ^H 
- - ‘ “ ‘ . . . ., . 
. • • ‘ 
I ANTI-IMPLANTATION 
ASSAYS IN RATS 
100 耀 C T R ® 
—10)- \ ； ：, 
\ YCK 
80- 、 \(n=10) 
0 \ x o ) \ 
1 6 0 - \ 气 
I V \ r 卜 \ \ . 
"20- • \ 




 -T T—1T— r 
n m 0.03 0.06 0.09
1
 0.12 0.4 0.8^ ' 16 32 ,
 1 
0.01 ‘ 0.1 1.0 . 10.0 
DOSE： MG/KG 
Fig. 11 : Dose response curve of yuehchukene (YCK) , 17〒咖 
ethynylestradiol (17a-EE2) and control (CTR) in an t i -




I . . .. 
* Substitution on the benzene ring led to the 
disappearance of act ivi ty . Both 2 , 5
1
— d i m e t h y l — Y C K (7) and 
2,5
1
—dimethoxy-YCK (8) were no七 active at 2 x O.E.D. and 4 x 
O.E.D. respectively, Table 1 (Fig. 10). 
Saturation of the C9-C10 double bond in 9,10-dihydro-
I 
YCK (9) did not affect act ivi ty at a l l . As a ma七ter of fact , 
• 
( 9 ) was equipotent with 七 h e parent compound when tested 
concurrently over a wide range of doses. While th i s resul t 
suggests that C9-C10 double bond is no 七 require for the 
expression of anti—implantation act ivi ty, 9 ,10-dihydroxy-YCK 
( 1 0 ) was not active at 4 x 0.E.D., Table 1 (Fig. 10)• 
•. … • 
Hydroxylation on the benzene rings also abolished 
act iv i ty . While 9,10—dihydro—YCK ( 1 0 ) was equipotent, 2,5，一 
dihydroxy-9,10-dihydro-YCK ( 1 1 ) was not active at 1.25 mg/kg. 
Although th i s dose was only 0.5 x O.E.D. , YCK (95% pure) 
tested at the same dose level in the same experiment was 100% 
active Table 1 (Fig. 10). 
R(+)—camphor—YCK (12) was tested over a 10-fold 
dose range (0.5-5 mg/kg, n=5 for each dose point).工七 was 
found to be 100% active at ,0.625 mg/kg. Even at 0. 5 mg/kg, an 
acceptable level of act ivi ty could s t i l l be observed. No 
toxic symptoms were observed at maximum dose level. 17a-
ethynylestradiol was 100% active at 0.12 mg/kg (Fig. 12). 
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I S(—）一camphor—YCK (13) was not active at 5 mg/kg, 
but on doubling the dose, 100% act ivi ty was achieved. Purity 
control by HPLC showed 七ha t S (-) -camphor-YCK was 93% pure, 
Since stereospecificity was determined by the s tar t ing 
material, ' ((IS)-(-)-camphor was only 95% pure), i t i s 
reasonable to assume that a small f r a c t i o n of S(-)-camphor-
YCK (13) could be actually R(+) -cainphor-YCK (12) . This 
explains the residual activity observed in; s(-)-camphor-YCK 
which must reach as high as 10 mg/kg 七o become active (Fig. 




-methyl substitution of (R)-camphor-YCK (Cpd 14) 
. . . ' 
could not increase potence, whereas 2丨一phenyl substitution 
(Cpd 15) drastically reduced act ivi ty to a residual 20 % 
relat ive potency (Fig. 12), Scheme 12, 
.一 j 
A number of analogues (Cpd 16 - Cpd 23) synthesised 
by Dr. K.F. Cheng were supplied to us for bioassay. These 
analogues show variation in covalent bond structure (Fig. 
1 3 ) . None of them was found active at the highest dose 
indicated except cyclopropyl-YCK (Cpd 23) . I t i s worthy to 
note that even epi-YCK (Cpd 20) was no七 active, although i t 
concerns here a change in configuration of the indane plane 
rather 七hSn a covalent structure (Kutney et a l . , 1989, 1991)• 
By 七 h e same token, A8'9 - YCK (Cpd 2 2 ) was not active by 





Table 1. A n t i — i m p l a n 七 a t i o n act ivi ty of substituted 
yuehchukene (YCK) derivatives 2-11 一 
雜—一麵麵痛一一 —•一 •輯膚輯書••講••一維"""麵•雄雄 
Dose No. preg./ Remark 




-Ac 6.0 5/5 -ve 
3 5-H 1»-Sue 2.4 5/5 -ve 
4 5-H 1
1
 -Me 7.5 1/5 +ve * 
5 5-Me 1» - Me 15.0 5/5 - ve 
6 5-OMe 1
1
-OMe 7.5 5/5 -ve 
工 工 . A r o m a t i c substitution 
7 2-Me 5
1





 -OMe 9.1 5/5 -ve 
工工工• C9-C10 saturation : * 1 
9
b
 9-H,Me 10-H,H - 3.0 0/8 +ve * 
1 0 9-OH,Me 10-OH,H 10.0 5/5 -ve 
IV. Aromatic hydroxylation 




1 YCK 1.25 0/5 +ve * 
VI. Vehicle control
d




also tested a七 5 mg/3cg with 100% act ivi ty 
(0/10) ； cYCK of 95% purity was treated in the same experiment 
as 11;
 d
control groups from a l l experiments in Table 1 had 
100% f e r t i l i t y . +ve denotes positive resul t indicating 2/5 or 
less; -ve denotes negative、result indicating 4/5 or more;, ±ve 
denotes equivocal resul t indicating 3/5 or equivalent; * 














R(+)-camphor-YGK (12) S(-)-camphor-YCK (13) 
0.625 mg/kg (+ve) 10.0 mg/kg (we) 
. - H
 y
 r ^ N f H 
r ^ V n f 〔 v i 
H f I] 
2,-Me-R(+)-camphor-YCK (14) 2'一Ph一R(+)-camphor-YCK (15) 
0.625 mg/kg (-f-ve) 3 .0 .mg/kg (+ve) 
, 、 - .. ' 
Fig. 12 : Anti-implantation activity of camphor-YCK and i t s 
analogues. The dosage shown is the highes七 dose (—ve) or 
lowest dose (+ve) tested in at least one group of ra ts (n=5) • 
Figure in bracket indicates 七 h e ser ial number of compound 
tested. 
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(Cpd 9) did not affect potency (see Table 1)• 
Inasmuch as YCK being a dimerisation product of 
MBDI, i t i s highly desirable to examine the anti-implantation 
act ivi ty of th i s precursor molecule and i t s congenors (Cpd 24 
-Cpd 33) (Fig. 14) . Indeed f MBDI (Cpd 30) was found active, 
albei t at a very high dose level (30 mg/kg) with concomitant 
toxici ty . The corresponding alcohol, 3-HMBI (Cpd 29) was also 
. 
active at a s t i l l higher dose level (40 mg/kg) when i t was 
substituted at C-3, but not at C-2 of the indole moiety (Cpd 
25) . But substituted 3~HMBI, whether on the indole nitrogen 
(Cpd 31) or on the aromatic ring (Cpd 26, Cpd 32) were not 
active. I t is shown above 七 h a 七 " t h e dimerisation products of 
these subs七ituted MBDI molecules were no七 active (see Table 
1) • in an attempt to synthesize benzofuran-YCK, the precursor 
benzofuran—3-HMBI (Cpd 33) was made and tested•工七 was not 
active at the same dose level (40 mg/kg) as i t s indole 
counterpart (Cpd 29) . The indole molecule (Cpd 24) and indole 
carboxaldehyde (Cpd 28) i t se l f were not active, nor was i t s 
substituted products like N-succinyl indole (Cpd 27) . This 
exercise demonstrated tha^: anti—implantation act ivi ty l i e s 
with YCK structure but not i t s constituent parts . 
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^ M ^ S V L C I 
!| j r 
H A ‘ 
. 
6,6a-Seco-YCK (16) Iso-Seco-YCK (17) 
31.75 mg/kg (- v e) 24,0 mg/kg (-ve) 
-
H 
. I I I 
H H : 
2—Biskatole (18) 6a—epi—YCK (20) 
10.0 mg/kg (-ve)
 8
 mg/kg (-ve) 
Fig. 13 : See figure legend overleaf. 
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3.Q mg/kg (-ve) ！ 0 . 0 mg/kg (-ve) 
H H 了八 z ^ — — n i ^ Y 
f i| ^ [ ij. 、 I i 
( l | I,
 H







-YCK ¢22) CP-YCK (23) 
2.5 mg/kg (-ve) 7:5 mg/kg (+ve) 
1
 .. % ' • -
Fig. 13 : Anti-imp1antation activity of analogues with bond 
varia七ioru The dosage shown is the highest dose (-ve) tested 
in a七 least one group of ra ts (n=5) . Figure in bracket 




C H 0 
I i \ 1 I , 
H H 
I , . . . 
• 丁 . 工 n d o l e — 3 — carboxaldehyde (28) 
Indole (24) 
10 mg/kg (-ve) 100 mg/kg (^ve) 
I - 一 . "‘ . 、 . 广 . ： … ， , ^ 
| 
• ‘ . . . . . . . . . , • 
「丨n ^ T y 
^ ^ 夕 彳 I . N i r 
I ^ ^ r V v 
o ^ ^ X c o o h
 0 H 
Succinyl Indole (27) 2-HMBI (25) 
10 mg/kg (-ve) 10 mg/kg (-ve) 
L ' F J 
H 
MBDI (30) 
30 mg/kg (+ve) 
Fig. 14 : See figure legend overleaf. 
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1 … ； V : . : : - 0H . . 0H • • 
T 1 1 ~ " i f L 丨丄 ij 
H
 H 
5-0H-3-HMBI (26) 3-HMBI (29) 
30 mg/kg (-ye) 40 mg/kg ( 十 v e ) 
• • . • 
O H 
OH- 丨 1 j 
从 N J : , ^ ^ r 
I . ‘ 
O M e 
5 - Me-3-HMBI (32) 
N-〇Me_3-HMBI (31) 
13.5 mg/kg (-ve) 
56 mg/kg (-ve) 
〇H 
I . . ^ > ^ 0 」 . " . . . ： : . . , . . 
Benzofuran-3-HMBI (33) 
40 mg/kg. (-ve) 
Fig. 14 : Anti-implantation activity of monomers. The dosage 
shown is the highest dose (-ve) tested in at least one group 
of ra t s (n=5).. Figure in bracket indicates the ser ia l number 
of compound tested. 
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• In order to investigate the possibility that YCK is 
actually a pro-drug activated by microsomal conversion to an 
active metabolite, proadifen (SKF-525A) supplied through 
courtesy of Smith Kline and French Laboratories was co-
administered with YCK at .recommended dose (50 mg/kg) and 
dosing schedule (2 doses at 12 hrs. apart) (Yard et a l . , 
1969)• Proadifen, a microsomal hydroxylation inhibitor, could 
not block the activity of YCK at effective dose range. 
P r o a d i f e n i七self could not affect arvti—implantation (Table 
Tamoxifen Is an anti-estrogen with residual 
estrogenic activity. In a series of experiments closely 
packed into a limited time frame of 8 weeks, estrogen 
sensit ivity of the rat colony was evaluated against YCK, Tain 
and EE2. Results in Table 3 show that while YCK was active at 
1.25 mg/kg and EE2 at 0.12 mg/kg which was 七 h e normal value 
for 100 % anti-implantation, Tamoxifen required only 0.03 
mg/kg to achieve the same effect. YCK at O.E.D. co-
administered with Tamoxifen over a thousand fold range ( 0. 01 
mg to 10 mg/kg ) did not affect YCK potency. By the same 
token, EE2 at O.E.D. co-administered with Tamoxifen over a 
300-fold range ( 0.003 to 0.1 mg/kg ) did. no七 affect EE2 




 T a b l e 2 Anti-implantation activity of SKF-525A and YCK in 
female ra ts 
C ^ u n d " : : " " ^ s l n g " No. preg / ^mark 
(mg/kg) Period No^^tested 
I . SKF-525A 50.0
 PD
2
 5 / 5
 “ 
TT vrv 1.0 PD2 5/5
 v e 
工工• Y 2 0 PD2 2/5 +ve 
3 0 PD2 1/5
 + v e 
1 5 PD2 4/5 
3 0 PD22 2/5 作 e 
一 . . 
+ e 
I I I . SKF-525A 50.0 + 1.5 PD2 0/5_ ； 









i-2 + v e 
2 5 PDi-2 丄 / 4 
1：5 Pd" 4/4 ^ e 
V. SKF-525A 15.0 + 3.0 PD2 0/5 = 
+ 5.0 + 3.0 PD2 0/5 = 
YCK 5 . 0 + 1 . 5 PD2 2/5 — 二 
3.0 + 1.5 PD2 3/5 士 = 
1.5 + 1.5 PD2 4/5 二 
1.0 + 1.5 PD2 3/4 -
v e 
A 
二 5 。 二 d d : 二 1 1 from at least one group of 
animal containing 5 ra ts . 
^ , ” •
 s
 « v 妨 v 
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Table 3 Anti-implantation activity of YCK and TAM in female 
ra ts 
Compound Dose No. preg./ .Remark 







YCK 0.31 9/10 -ve 
0.62 2/10 +ve 
1.25 0/5 +ve • 
1¾ .,: ‘ ‘ . 减 
YCK + TAM 1.25 + 0.01 0/5 二： 
1.25 + 0.03 0/5 +ve 
1.25 +0.10 0/5 +ve 
1.25 + 0.30 0/5 +ve 
1.25 + 1.00 0/5 +ve 
1 .25+3.00 0/5 +ve 
1.25 + 10.0 0/5 +ve 
TAM 0.003 ' 5/5 ;ve 
0.010 2/5 +ve 
0.030 0/5 +ve 
0.100 0/5 +ve 
0.300 * 0/5 +ve 
1.000 0/5 ±ve 
3.000 0/5 +ve 
E2 0.12 1/5
 + v e 
+ TAM 0.12 + 0.003 0/5
 + v e 
2
 0 . 1 2 + 0 . 0 1 0 1/5
 + v e 
0.12 + 0,030 0/5
 + v e 
0 . 1 2 + 0 . 1 0 0 0 / 5 一 二 = 一 一 一 
result from at least one group of 
animal containing at least 5 ra ts . 
8 6 
‘' I 
3.2.2 Uterotrophic Activity 
When 1 7 a - e t h y n y l e s t r a d i o l was used as a posit ive 
I 
control in 七 h e an七i一implantation assay, i t showed a dose 
response curve paral le l to YCK reaching 100% act ivi ty at 0.12 
mg/kg and 1.6 mg/kg respectively. At 50% maximal ac t iv i ty , 
YCK carried 8.2% estrogenicity in an七i-implantation assay 
(Fig. 15). Dosing at PD^ only gave the same re la t ive 
estrogenic potency• 
When 17a-etliynylestradiol was used as a positive 
control in uterotrophic assay, i t showed a linear dose 
response curve reaching a plateau at 0.03 mg/kg. The dose 
response curve of YCK followed a slower r is ing slope in a 
less paral lel manner, reaching a plateau at 0.3 mg/kg which 
was 2/3 of 七 he maximal response by EE2. At 50% maximal 
act ivi ty, YCK carried 4.5% estrogenicity in uterotrophic 
assay. This resul t holds true in several experiments using 
YCK from different batches (Fig. 2) • 9,10-dihydro-YCK (9) 
which was equipo 七 exit in ant i—imp Ian七 at ion was also 
uterotrophic but soon reaching a plateau at 0.1 mg/kg at 
50.6% maximum increase of、 uterine weigh七 by EE2. N-l,,N—5-
dimethy-YCK (5) and 2 , 5 ， - d i m e t h y l — Y C K (7) were not active 
even a七 3 mg/kg and 5 mg/kg respectively. However, N-l , -
methyl-YCK (4) was active at 1 mg/kg. At th i s dose level, i t 




p positive response only began at this dose level (Fig. 15)• 
Uterotrophic response in immature rats showed that 
R(+)-camphor-YCK (12) had a similar level of estrogenic 
potency as ( 士 ） 一 Y C K (1) over a 30—fold dose range. At 50% 
maximum activity, both compounds carried 3 - 5 % relative 
potency with respect to the positive control, 17a— 
ethynylestradiol. A slow rising slope over the linear range 
of dose response and a diminished plateau suggested that 
R(+) -camphor-YCK (12) and (±) -YCK (1) were weak estrogens but 
behaving like a partial agonist in 七 he expression of 
estrogenic activity. 
S (-)-camphor-YCK (13) was much weaker than R(+)-
camphor-YCK (12) in a s t i l l slower rising slope. I t carried 
less than
-
3% residual activity with respect to R(+)-camphor-
YCK (12) and i t s relative potency was insignificant (less 
than 0.1%) when compared with the reference compound 17a-
ethynylestradiol (Fig. 16)• 
3.2.3 Blue Test 
Under normal physiological conditions, implantation 
si tes became detectable in 七 he morning of PD5; by the 
afternoon, most of the rats revealed distinct blue spots. 
When (±)—YCK was administered at 0.626 mg/kg, there was no 
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F i a . 15 : Dose response curve of 17a-ethynylestradiol ( O ), 
YCK ( A ) , Dihydro-YCK ( 鼸 ） ’ N - l - M e t h y l - Y C K ( ® ^ 
Control ( •) i/uterotroplxic act ivi ty in 
point is the mean of eight determinations ； S.E.M. was l e . s 
than 10% of the mean for each point. 
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Fig. 16 Dose response curve of 17o:-ethynylestradiol ( •), 
YCK ( • ), R(+) -camphor-YCK ( • ), S (-)-camphor-YCK (琴 ) 
and Control (symbol in the ordinate) in uterotrophic activity 
in immature rats . Each point is the mean of five closely 
agreed determinations ； S . E . M . was less than 10% of the mean 




implantation s i te at a l l . I t was only at half of this dose 
( i .e . 0.31 mg/kg) that blue spots were detectable in the 
morning of PD6/ a delay of 12 - 24 hours with respect to 
vehicle control (Table 4). 
R(+)-Camphor-YCK (12) could completely prevent 
implantation at 0 .62 mg/kg; only 1 ra t with 1 implantation 
s i t e was observed in the morning of PD6. At half of this dose ^ •. . ‘ 
(0.31 mg/kg) , blue spots were detected randomly in the 
morning of PD5 and again in the morning and afternoon of PD6 
(Table 4) • In a l l 3 positive groups, there were ra ts with 
very few implantation s i tes clustered at the dis tal end of 
the uterine horn, showing a perturbing effect on blastocyst 
transport. This delayed appearance and errat ic distribution 
of implantation si tes were also observed in rats treated with 
0.12 mg/kg of 17a-ethynylestradiol. In this case, the late 
implantation si tes on PD6 were few and clustered. In contrast, 
blue spots were observed in the morning of PD5 and again in 
PD6 showing that S(-)-camphor-YCK (13) was not active at 2.5 
mg/kg which is 4 times higher than the dosage of R(+)-
I 
camphor-YCK (12) (see Table 4) • 
•… ‘ - [ ,• .
 ;
 1、 
Previous attempts to recover tubal eggs af ter YCK 
administration showed that at effective anti-implantation 
dose level, YCK caused accelerated tubal transport and zygote 
fragmentation (results not shown). 
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： r—————— . 
Dale of Autopsy … , 
rr- , ‘ Treatment 
(Time) 
Control E2 YCK 
0.12 mg/kg 0.62 mg/kg 0.31 mg/kg 
PD 4 (15.00-16.40) - - _ 一- - - - - -
PD 5 (11.00-12.00) - - 十 - + 十十 - - - - “ 
PD 5 (14.25-15.25) 十 十 + _ + —— 
PD 6 (10.15-12.15) + + + + + _ - 十 - + +十十 + 十 
PD 6 (14.30-15.50) _ + + 十 十 — + . 1 維 - + + • 十 十 
Date of Autopsy 斤. 、• • Treatment 
(Time) 
: 一： “ C o n t r o l R(+)-Camphor-YCK S(-)-Camplior-YCK 
0.62 mg/kg 0.31 mg/kg 2.5 mg/kg 
P D 4 (15 .00-16 .40) - - - - - - — - - - - ： - … - .： 
PD 5 (11.00-12.00) - - + - + 十十 十+ + - - \ ；| ‘ 
PD 5 (14.25-15.25) 十 + 十 - + - - — — + 十 + - 十 . -
PD 6 (10.15-12.15) + + + 十+ . - + - - - - 十 - + 十 十十+ + + 
PD 6 (14.30-15.50) - + 十 + + +十+ + - 十 + 十+ + 
* • 
, . 、 
Table 4 ： Results of yuehchukene (YCK), 17a-ethynylestradiol 
(EE2) , R(+) -camphor-YCK, S (-)-caitiphor-YCK on delayed 
implantation assay. Drug was given intragastrically at the 
indicated daily dose from Pregnancy Day 1 to Day 4 (PDM) • The 
Blue Test was performed as described 111 Materials and 







J 3.2.4 Binding Assays 





A binding displacement curve was observed with 
around 0.3 jLtM YCK; at th is concentration i t was able to 
inhibit 50% of 3 nM [
3
H]-E2 binding indicating that YCK i t se l f 
was able to compete for the estrogen binding s i tes . In 
another experiment, pretreatment of cytosolic receptor with 
various concentrations of YCK followed by addition of labeled 
estradiol showed a similar binding curve as shown in Fig. 
17 • I t indicated that the binding of YCK towards the estrogen 
receptor was reversible. 
I . • 
3.2.4.2 Liver Microsomal Anti-Estrogen [
3
H]-Tamoxifen 
Receptor Binding Assay 
Fig. 18 demonstrated the specific binding of [
3
H]-
Tam to anti-estrogen binding s i te in 七 h e presence of DES. 
Cold Tam displacement of [
3
H]-Tam binding was dose dependent 
in a sigmoidal. curve; 50 % inhibition was observed at a 
conceivtra七ion of 10 nM. YCK was able to inhibit the binding 
of [
3
H]~Tam to DES, but only at high concentrations. Effective 
displacement of [
3
H] -Tam binding began at approximately 10 /iM 
• ^ ¥ ，： •  . . . . . .
 3
 ' - - “ 广 
YCK and progressed precipitously af ter 100 /xM. 50 % binding 
• • . , 、 
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Fig. 17 : Immature female rats uteri cytosol was incubated at 
4°C with 3 rM [
3
H]-Estradiol with increasing concentrations.of 
yuehchukene ( • )• Pretreatment of uteri cytosol with 
increasing concentrations of yuehchukene (A) before addition 
of 3 nM [
3
H] -Estradiol was performed under the same conditions 
as described in Materials and Methods. Binding of [
3
H]~ 
Estradiol in samples, determined af ter 2 0 hrs. competition by 
charcoal suspension, is plotted against the concentration of 
yuehchukene. 
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Fig. 18 : Ligand specificity of. anti-estrogen binding 七 e s 
of ra t l iver. [
3
H]-Tamoxifen was incubated with rat Irver 
20,000 g supernatant in the presence of various amounts of. 
tamoxifen ( ® ) and yuehchukene (醒）• Details are described 
In Material's and Methods. 
F .:.. . . . : , . . , .、、： ： . . . _ • . : , . : ^ ‘. 




inhibition was observed at around 300 jiM YCK. 
3.2.5 Enzyme act ivi ty 
I 、,， -
3,2.5.1 Ornithine Decarboxylase Activity Assay 
The effects of single injections of DES and TAM at 
a dose of 20 jug/kg 七 o g e t h e r wi七h or without YCK at a dose of 
2 mg/kg were studied (Fig. 19) . DES showed an increase of 750 
% ODC act ivi ty as compared to the control (100 %) while TAM 
only increased marginally by 120 %• YCK stimulated a lower 
level of act ivi ty (400 一. 500 %) than DES but i t was much 
higher than the control, suggesting that i t was acting like 
a weak estrogen. YCK was able to antagonise par t ia l ly (600 -
650 %) the- effect of DES when they were injected together 
indicating that YCK could not ful ly stimulate uterine 
polyamines synthesis (Janne et a l . , 1978). When TAM was co-
injected with YCK, ODC activi ty (500 %) was much greater than 
TAM i t se l f but lower than- YGK plus DES. This mitigated 
response of E or AE in the presence of YCK suggested that i t 
was a par t ia l estrogen (Fig. 19). 
3.2.5.2 Glucose-6-phosphate Dehydrogenase Activity Assay 
Glucose-6-phosphate dehydrogenase (G-6-PD) activity-
was increased 1.8-fold af ter 20 hours following a single 
• . .
 1
 . . . . 
injection of DES while YCK also stimulated a 2-fold increase 
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F i a 19 ： Ornithine decarboxylase activity (ODC) measured 20 
hours after a single treatment of 20 fig/均 dose of compound 
except YCK which was administered at a dose of 2mg/kg. Groups 
of 4 immature female rats were injected subcutaneously with 
vehicle or compounds as, indicated. Animals were killed. 20 
hours after injection and uteri were removed and immediately 
assayed for ODC activity as described in Materials, and 
Methods. Results are expressed as % control from duplicate 
samples and 醒 , S represent two separate experiments. 
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Fig. 20 : Stimulated response of glucose—6—phosphate 
dehydrogenase (G—6—PD) levels after a single treatment of 
compounds. Groups- of 4 immature female rats were injected 
subcutaneously with vehicle or varying doses of compounds as 
indicated. Animals were killed 20 hours later and uteri were 
removed and immediately processed for G-6-PD assayed as 
described in Materials and Methods. Results are expressed as 
mean 士 S.E. from two separate experiments. 
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(Fig. 20). TAM was ineffective and enzyme activity remained 
at control level. When DES was administered together with 
YCK, there was also no further increase in enzyme activity, 
indicating that both were already acting maximally. By the 
same token, when Tam was administered together with YCK, 
enzyme activity increased to the same level as YCK alone. 
I I I • v ' I ^^^H 
This experiment was repeated using suboptimal doses 
of the t es t compounds. Dose-dependent reduction in the 
1 
increase of enzyme act ivi t ies was observed in DES and YCK 
while Tam always remained ineffective. But when suboptimal 
doses of DES and YCK were administered together, there was no 
additive effect , By the same token, suboptimal doses of Tam 
and YCK administered together stimulated enzyme activity to 
the same extent as in YCK alone. 
3.2.6 MCF-7 Cell Growth Response 
MCF-7 breast cancer cel ls were deprived of estrogen 
and then replaced at mainteriance level (10
4
°M) without showing 
stimulation of proliferation. YCK (10'
9
 - 10¾) added to the 
culture in the absence of•estrogen showed anti-proliferative 
effect which was not dose-dependent. The same level of YCK in 
the presence of E2 (10
-
¾) which induced a minimal amount of 
ER in the cell (Harris et a l . , 1991) showed more pronounced 





When replacement of E2 was raised to lcr
9
M, whereby 
ER were induced in the cell (Harris et a l . / 1991) , a 32% 
stimulation of proliferation over control was observed. YCK 
per se at 10"
9
M could inhibit proliferation by a 23% decrease 
with respect to control, but E2 (10¾) in the presence of YCK 
(10¾) could only marginally stimulate cel l proliferation to 
an increase of 13.8% (Fig. 21B) . Con A stimulated human 
peripheral blood lymphocytes transformation (Ng et al , , 1986) 
was used as a tes t of cell viabi l i ty . Preliminary results 
showed that YCK (1.4 nM) or indole at 1,4 /xM had no effect on 
Con A stimulated cell division (results not shown)• 
I t could be concluded from these two experiments 
that YCK had a direct anti-proliferative effect on breast 
cancer cel ls in culture and 七 hat cellular response to 
estrogen treatment was mitigated in the presence of YCK. 
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M) were added to the culture 
respectively with or without E2 (10"
10
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Fig. 21 B : MCF-7 breast cancer cel ls were treated with 
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I Chapter Four 
4 Discussion 
4.1 Species Specificity 
The anti-implantation act ivi ty of YCK was routinely 
evaluated in ra t s . The ra t is an ideal animal model for 
f e r t i l i t y study because of i t s high and cionsisterrt f e r t i l i t y 
ra te . But the ra t is a less than ideal bioassay for anti— 
implantation studies, Rats have lower estrogen level during 
early pregnancy than other species and are therefore very 
sensitive to estrogen action (Hahn et a l . , 1974). In ra t s 
ovariec七omised soon af ter successful mating (on PD3) , the 
embryos were held in a state of diapause. A small dose of 
estrogen (0.01 mg) could induce implantation in ra t s thus 
treated; higher dose (4 mg) would inhibit implantation and 
cause embryonic death (Cochrane et a l . , 1981). Therefore, 
early attempts 七o develop pos七一coi七al arrti—fertility agents 
using the ra t model ran into estrogenic compounds like ORF 
4563 (Yard et a l . , 1969) and ORF 8511 (Hahn et al . , 1974) • I t 
was conducted 七 h a 七 the la t te r exerted i t s an t i - f e r t i l i t y 
: • • . . . . . v , . . . . ； 
effect through mechanisms related to i t s estrogenicity. 
• 
YCK was active in mice at a much higher dose (6 -
7 mg/kg) in several experiments, following the same dosing 
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schedule as in rats (Y.C. Kong, unpublished results) . 
I、 ^^ 
工 m p l a i v t a t i o r i in hams七er was not sensitive to estrogen, but 
here YCK was not active even at elevated doses. The problem 
l ies in a low and inconsistent f e r t i l i t y rate in this 
species, necessitating a large number of animals in each 
group in order to achieve s ta t i s t ica l significance (Y.C. 
Kong, unpublished results) . Better results were reported in 
guinea pigs； although not as neat as in rats . Here, YCK could 
cause a reduction in l i t t e r size only (Hammarstrom et a l ” 
1990). YCK was not active in marmosets, a mens 七 ruating 
primate, even at 5xr rat effec七ive dose (Prof, J. Hearn, 
Z o o l o g i c a l Insti七ute, London, W.H.O. in-house data no 七 
published)• 
While the rat model is apt to pick up estrogenic 
compounds, " this diffused species specificity might also 
reflect the diversity of implantation mechanisms in different 
species. Estrogenic compounds may block implantation in women 
through other mechanisins • In a serious attempt to look for 
poS七一coitar ariti—fertility agents, a pharmaceutical house in 
Europe (Lepetit, Milano) synthesised a series of isoindoles 
and isoquinolines. Structure-activity relationship of these 
compounds had been studied with rats and hamsters, which 
showed that the active compound was much more potent when 
tested in hamsters. But this type of synthetic products had 




utero-placental unit rather than the prevention of 
implantation (Toja et a l . , 1982). To sum up th is situation, 
f e r t i l i t y regulation s t i l l awaits the availabil i ty of a non-
I • t .-
steroidal non-estrogenic anti-implantation agents. 
' . 
4.2 Estrogenic indoles 
I. 
Indole compounds usually manifest biological 
ac t iv i t ies , many of them are useful drugs that have withstood 
the tes t of time, e.g. strychnine (CNS stimulant) r 
catharanthine (an七i_cancer)• eraotamine (anti-migraine), 
reserpine (hypotensive) and with modification of the indole 
moiety, quinine (anti-malarial) and physostigmine (CNS-
arousal). Coronaridine (see page 9) from Tabernaemontane 
hevneania (Apocynaceae) is the only estrogenic derivative 
reported in'natural products (Mehrota, 1978) (Fig. 22) . I t is 
much weaker than YCK in anti-implantation assay. I t s 
structure indicated that i t is the product of quite a 
different biogenetic route than YCK. Indomethacine,‘ a 
synthetic compound, has no estrogenic activity, but i t may 
counteract estrogen action through 七 he inhibition of 
prostaglandin synthesis,, which mediates some aspects of 
estrogenic activity, e.g. uterine contraction. Thus, i t is a 
rare opportunity to have discovered YCK with such a high 
level of relative estrogenic potency (Kong et a l . , 1985a)• 
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I Early attempts to synthesise estrogenic 
triphenylethylenes came up with a 2,3-diphenylindole design 
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This structure could be an effective ant i -
implantation agent, albeit at much lower potency (10 mg/kg, 
‘dosing PD", p.o.) than YCK, if a diethylaminoethoxy side 
chain, or a similar basic alkylamino group, was substituted 
at the para-position of the 2-phenyl ring (Iyer and 
Gopalchari, 1966) . The presence of th is group is a pre-
requisite for the anti—estrogenic effect in tamoxifen (Murphy 
et a l . , 1990) , I t has been shown that a stra七egically located 
alkylaminoethoxy side chain in cyclofenyl' a 
diphenylmethylenylcyclohexane, would turn an estrogen into 
an t i - e s t rogen (Garg et a l . / 1983)• The 
diphenylmethylenyleyclohexane structure is very estrogenic as 
in ORF 8511 (Hahn et al. , 1974) . If YCK is rewritten as 
1,1,1-di-indolylcyclohexenyl methane, i ts estrogenicity 
became very obvious because of i ts close similarity to ORF 
8511. " 
ORF 8511 
YCK iP、、、 !^^ 
H 107 
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An alternate approach to YCK synthesis involved the 
fusion of the indole moiety with the indene moiety by 
cyclisation of the divinylketone (Bergman and Veneitialm, 1988; 




 I I 
^ y y 
YCK might be cleaved metabolically to yield an . 
active structure as shown in previous page. In this case, the 
relat ive contribution of the indole nitrogen in YCK to 
estrogenic and anti—estrogenic activities might be accounted 
for. 
4.3 Conservative structure 
While YCK is a rare example of an estrogenic 
indole, i t is even more surprising to find that i ts 
estrogenicity lies in a very conservative molecular design. 
The indole nitrogen stands out as the most distinguishing 
chemical feature in an estrogenic compound and i t is easily 
amenable to chemical modification. Early attempts in 
structure modification were focused on 七 h e nitrogen. As a 
matter of fact,七he f i r s t analogue obtained was a N1—ace七yl似 
YCK, which crystallized to give a sample f i t for X-ray 
108 
diffraction study. But i t was disappointing to find that 
tampering with indole nitrogen abolished activity, even by 
substitution with a smaller non-polar group like N-
methylation. YCK could tolerate the introduction of one 
methyl group on the free indole nitrogen, with substantial 
loss in activity. With N,N
1
-dimethyl-YCK, anti-implantation 
activity was lost but uterotrophlc activity was barely 
detectable at a very high dose level. N-methoxylation was 
intended to produce a slow releasing analogue and (Acheson 
and Nwankwo, 1984) N-l
1
-succinylation was iivbended to produce 
a wa七er soluble analogue. Both attempts at modifying 七 h e 
pharmacokinetics sacrificed the anti-implantation activity. 
工七 is suspected that neither the size (me七hoxyl vs succinyl 
groups) nor the polarity (methyl ve methoxyl groups) of the 
substitutent on the nitrogen matters (Chan et al.,1991), i t 
is the nitrogen atom i tself playing a determinant role in the 
expression of biological activity. In order to prove this 
point, protracted efforts to make benzofuran-YCK were made 
but were met with failure. I t had been possible to go as far 
as benzofuran-3-HMBI, but the la t ter refused to dimerise like 
MBDI. Perhaps benzofuran-YCK may not be active at a l l . MBDI 
was active because i t could probably dimerise in vivo under 
acid conditions in the stomach to give YCK. Likewise, 
benzofuran—3—HMBI might give benzofuran-YCK in vivo but i t 
was not active. 
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In a similar vein of research efforts like the 2,3-
diphenylindole, the same group (Central Drug Research 
Inst i tute , Lucknow) synthesised 2,3-diphenylbenzofurans and 
found them poor molecular designs as the triarylethylene and 
triarylpropenone. I t was postulated that interaction of 
oxygen atom, with a higher electronegativity, on the receptor 
s i te may lead to atypical binding, hence unsuccessful 
activation (Durani et a l . , 1989). But with tamoxifen, the 
introduction of a sulphur atom into trioxifen to give a 
benzothiophene as in the LY-series made i t a better ant 1--
estrogen with less residual agonist activity (Black and Ford, 
1980). These evidences, though circumstantial, all hint at 
the involvement of the lone pair of electrons in N and S' 
possibly through electron transfer during ligand—receptor, 
binding. In this case, i t might be useful to compare the 
activity in indane, indole, benzofuran and benzothiophene 
types of YCK analogues. ‘ 
( " ^ V i ^ i ^ r n ^ f ^ i n f 
W ^ n 人 j 人 ) ^ ^ s 人 j 
Indane Indole Benzofuran Benzothiophene 
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4 . 4 Hydroxylation Site 
Since the phenolic hydroxy1 group is the 
determinant structural feature in estrogen action by 
in i t ia t ing receptor binding (Duax et al養 ,1985), i t i s 
generally assumed that YCK must be hydroxylated to become an 
active metabolite. 2, 5
 1
-dimethyl-YCK was not active, probably 
through hindrance of hydroxylation at the C-3 and C-6
1 
positions. Methyl substitution at C-2 in estrone abolished 
activity (Dorfman and Kind, 1966) . 4-OH-Tam has lOOx higher 
binding aff in i ty to ., ER than Tam,七his accounts for i t s 
correspondingly greater anti-tumour potency than Tam in 
vitro, e.g. in MCF-7 cell culture (Jordan et a l . , 1977). 
Early attempts to look for non-steroidal post— 
coital an t i - f e r t i l i t y agents produced estrogenic compounds 
like ORF 4563 (Yard et al . , 1969) • I t was more active by oral 
route and i t s activity was antagonised by proadifen (SKF-
525A), a microsomal hydroxylation inhibitor. This implied 
that ORF 4563 was f i r s t hydroxylated at the para-position of 
the phenolic ring before i t could exert i t s activity. An 
analogue thus hydroxylated, ORF 6218, was not blocked by 
proadifen. In our hands, proadifen at recommended dose (50 
mg/kg) could not block YCK activity (see Table 5)• This may 
be taken to mean that YCK did not undergo hydroxylation to 
become active. On the contrary, YCK i t se l f may even act on 
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the cytochrome P-450 system since i t is structurally related 
I,:.,: . 
to ellipticine, a pyridocarbazole and a known inhibitor of 
cytochrome P-450 but i t did not bind to AEBS (Lyman and 
Jordan, 1985)• 
I ellipticine M e 
i I r . j. 
H Me 
Indeed, synthetic hydroxyl-YCK was not more active as in 
2,5
,
_dihydroxy_9,10_dihydro~YCK (1.25 mg/kg, 一 v e ) , or not 
active at all in9,10-dihydroxy-YCK (lOmg/kg, -ve). This 
surprising result may be explained along several lines. 
9、, 10-dihydroxy-YCK would resemble 3-deoxy-estriol 
I . 
in structure. Estriol is a weak agonist and 3-deoxy-estradiol 
has poor binding affinity to ER (Borgna and Scali, 1991)•工n 
any case, hydroxylation at a position other than the C一3 
position of the phenol ring would mis-direct the ligand in 
receptor binding. 
. . 
‘ . - -
. ^ • 
The loss of activity in 2,5
1
-dimethyl-YCK has been 
deal七 with above , but the loss of activity in 2 , 5 1-dimethoxy-
YCK is no七 easy to explain. The methyl ether of estradiol 
(mestranol) has poor binding affinity but manifests high 
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potency in vivo (Eisenfield, 1974). Demethylation of the 
methyl ether to phenol i s a primary route of metabolic 
activation for several phytoestrogens and insecticides 
(Jordan et a l . , 1985) . If demethylation did take place in our 
case, i t would only give an inactive 2 ,5
 1
 -dihydroxy-YCK which 
i s the same as 2,5•-dihydroxy-9,10-dihydro-YCK, saturation of 
C9-C10 double bond did not affect the anti-implantation 
act ivi ty at a l l (see Table 1)• 
There are two possible consequences following 2,5
1
-
hydroxylation. The compound could be further hydroxylated at 
the C-3 and C一61 positions, as they are the preferred s i te of 
aromatic hydroxylation. This would give a catechol 
derivative. Catechol estrogen is less active (Fishman, 1978; 
Dickson, 1980). Even without 七 h e intervention of the 
cytochrome P-450 system, a hydroxylated derivative, whether 
at the aromatic ring or the hexenyl ring, would make i t se l f 
more susceptible to hepatic conjugation. In MCF-7 cells , 4-
OH-Tam glucuronide has reduced potency due to the inabil i ty 
of the cells to hydrolyse the glucuronide back 七 o 4-OH—Tam 
(McCague et al . , 1990) • In the ra t , i t would be reasonable to 
assume 七 h a 七 YCK conjugated with glucurona七e or sulphate i s 
readily cleared through renal or hepato—enteric routes, thus 
cutting down the duration of action. 




culture experiments showed that YCK could exert an ant i -
prol i fera t ive effect . By the same token, in uterine ER 
binding experiments, YCK could effectively displace labeled 
estradiol binding.工n both cases, hydroxylation i s not 
involved. However, before we could conclude 七 h a 七 YCK does not 
require hydroxylation to become active, i t i s necessary to 
compare the potency and pharmacokinetics of YCK with i t s 3-OH 
and/or 6,-011 derivatives. I t is not surprising to find out 
that whereas hydroxylated YCK binds to ER as a weak agonist, 
i t might bind to AEBS as such to exert some aspects of ant i -
estrogenic act iv i ty . 
4.5 Configuration and constraints 
The basic molecular design for an estrogen is the 
estra-1,3,5 (10)-triene which has only weak estrogenic 
act iv i ty . Various substituents exert a d i f fe ren t ia l effect on 
i t s potency which is a summation of receptor binding and 
activation. Thus hydroxylation at C-3 position of the phenol 
ring could greatly increase binding a f f in i ty to ER, but i t i s 
hydroxylation at C-17 in a 冷 一 p o s i t i o n 七 h a t imparts biological 
act ivi ty (Chernyaev et a l . , 1975). Introduction of a 17a— 
ethynyl group greatly increased receptor binding (2x over E2) 
and oral act ivi ty . But even then the stereospecifici ty of 
th is protective group manifested stereochemical preference. 
When 七 he ethynyl bond was reduced to give a halovinyl 
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derivative in two steps through hydrostannation by 
t r ibu ty l t in hydride and followed by electrophilic 
destannylation, i t could present i t se l f in two forms, viz. 
17a,E and 17a,Z halovinyl estradiols. C一20 stereochemistry 
affected receptor binding and the Z isomer had a 
significantly higher relat ive binding aff in i ty , especially 
better with larger halogens (I, Br) than smaller ones (CI) 
(Napolitano, 1991)• 
Z Form , E Form 
Diethylstilbestrol is a synthetic estrogen mora 
potent than the natural product (E2) , with correspondingly 
higher aff in i ty binding. I t s structure is based on the 
stilbene core of which the trans-configuration resembled 
estrane, while 七 h e cis-isomer was inactive, at best a weak 
anti-estrogen (Jordan, 1985). A sh i f t of the double bond to 





While aff ini ty binding was more or less the same in these 
pseudo analogues, uterotrophic activity was greatly reduced 
in Z-pseudo-DES which was further halved in E-pseudo-DES 
— 一 . 
A more complicated situation prevailed with the 
triphenylethylenes such as tamoxifen and clomiphene. In the 
t 
former, the trans isomer is a potent anti—estrogen but the 
cis isomer is only a weak estrogen (Duax et a l . , 1985). In 
I . _ 
clomiphene, the trans isomer (enclomiphene) is a part ia l 
agonist with anti-estrogenic activity; the cis isomer 
- "“ I 
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Even without th is trans-cis transition in a fixed 
？”： . ' 
ring tamoxifen, the placement of 2 different substitution 
groups (hydroxyl and alkylaminoethoxy) on 3 phenol rings gave 
r i se to a complex situation but generally obeyed the 
correlation between binding af f in i ty and potency (Murphy et 
a l . • 1991)• The counterpart of a fixed ring tripheny1ethylene 
occurred naturally with diethyls七ilbestrol. The oxidative 
product gave r ise to an indene ring in two forms, the 
indenestrol A (IA) and indenestrol B ( IB) : 
oh 、 
( 工 A ) (IB) 
These oxidative metabolites have the same binding aff in i ty as 
their parent compound, but with much weaker uterotrophic 
activity• The fused indene ring ixvtroduced a chiral centre a七 
C-3 but not in C_1 which was not possible because of the 
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C-1,2 double bond. Now IA as a racemate could be resolved 
into i t s enantiomers by chiral column (Chae et a l . , 1991) as 
IA(C3)-S and IA(C3)-:R, only IA(C3)-S was biologically active. 
While IA—racemate retained only half of the binding a f f in i ty 
as i t s parent compound (Kd 0.35 nM),工A(C3)—S had completely 
regained th i s a f f in i ty (Kd 0.37 nM) whereas IA(C3)-R 
suffered a near-total loss (Kd approx. 8.1 nM) . Demethylation 
of th i s chiral group greatly reduced receptor binding (Kd 
approx. 3.5 nM) and po七ency (Korach, 1991). These examples 
eloquently speak for the finely tuned stereospecificity of 
the estrogen receptor. :::'、 
Since YCK is a racemate and i t i s believed to bind 
to ER to exert i t s act ivi ty (see resul ts on receptor 
binding) , i t is reasonable to assume 七 h a 七 only one of i t s 
enantiomers is active. The f i r s t hint that YCK manifested 
stereospecifici ty came from the observation that epi-YCK (Cpd 
20 in Fig. 13) was not active. More than the identif ication 
of an active enantiomer7 i t i s of paramount impor七ance to 
find out if the anti-imp1antation and uterotrophic ac t iv i t ies 
of YCK could be dissociated stereochemically. 
Bioactive enantiomers often show a d i f ferent ia l 
act ivi ty prof i le . A classical example is adrenaline in which 
the naturally occurring levorotatory isomer is 50 - 100 times 




Depending on application, both enantiomers are sometimes 
I V 
equipotent in thei r main function but have different side-
effects e.g. the anti-malarial act ivi ty of quinine 
i / • • 
(levoro 七 atory) i s the same as that of quinidine 
(dex七rorotatory) , but 七 h e l a t t e r has a much more potent 
cardiac effect . A recent example is (±)-gossypol, in which 
only the (-)-isomer i s useful for suppressing 
spermatogenesis, Unfo:rtuna七ely, the toxic effects also reside 
in th i s optical isomer although the distr ibution of other 
pharmacological properties between the two isomers i s by no 
means equal (Yu, 1987). 
YCK has three chiral centres, therefore natural YCK 
and synthetic YCK are racemates. If the biological act ivi ty 
of YCK is stereospecific with respect to the position of C-6 
indole relat ive to the te t racycl ic plane, only one of the 
eight enantiomers could be active. The present resul ts 
support th i s hypothesis as R(+)-camphor-YGK was much more 
potent than S-camphor-YCK• The residual act ivi ty (about 
5%) in the l a t t e r could be considered a resul t of 
contamination if absolute stereospecifici ty i s to be the 
rule. This assumption seems to be fa i r as the s tar t ing 
material, S(-)-camphorf was only 95% pure. In contrast, 
camphor had a higher enantiomeric purity and was 99% pure. 
Consequently, i t was deduced tha七 only that enantiomer of YCK 
which was represented by R(+)-camphor-YCK was the 
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biologically active form. 
One major reservation in developing YCK as an ant i -
f e r t i l i t y agent for human use is i t s estrogenicity. One major 
chance to resolve this problem is to synthesise a 
stereospecific isomer and see whether the anti-implantation 
activi ty and estrogenicity are dissociated. The ensemble of 
bioassay results indicate that both anti-implantation and 
I . 
uterotrophic act ivi t ies reside in the same ster ic isomer. In 
quantitative term, YCK and R(+)-camphor-YCK are equipotent 
for anti-implantation and the prevention of pregnancy is 
actually due to the blockage of blastocyst implantation 
s i tes . Whether th is . i s the result of accelerated tubal 
transport, or suppression of endometrial receptivity, or even 
a blastocidal effect is not clear. Inasmuch as YCK and R(+)-
camphor-YCK are also equipotent for the uterotrophic 
response, i t could be concluded that YCK exerts i t s ant i -
implantation effect through i t s estrogenicity. Since the YCK 
structure is quite different from that of estrogens, the 
compatibility between the YCK configuration and the estrogen 
receptor remains to be studied. 
In a detailed study on the rotation of 七 h e C-6 
indole in YCK, a series of C-7 functionalised analogues (Fig. 
23) were made by Cheng et al . (personal communication) base on 
the stereoselective synthesis of the key intermediate, 7-Nor-
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te t racycl ic carboxylate (Cheng et a l . , 1990). 工七 was 
concluded that a sizable spacing group at C-7 position was 
I . 
indispensable. Whereas the potency of an analogue was -
I 
weakened by reducing (7-Nor) or increasing (7-Nor-7_BM) the 
size of the substl tutent, C-2
1
-methyl substitution on the 
free indole could help to regain some act iv i ty (Cheng et a l . f 
1991) • i t seems that as far as anti-implantation i s 
concerned, a C-7-gem-methyl group i s the best molecular 
design afforded by nature. Although 2,—methyl-YCK had not 
been synthesised, 2
1
-Me-R(+)-camphor-YCK showed no increase 
in potency (see Fig. 1 0 ) . I t could be concluded from these" , 
configurational considerations that the two indole moieties 
were pushed towards each other in a berrt molecule with an 
inflexion point at C-6. Ben七 molecule i s of course a far cry 
from the relat ively planar conformation of estrane. Thus 
indanes七rol ( 工 N D C ) lost both binding a f f in i ty and potency 
because of a non-planar right angle structure by saturation 
of the double bond in indene (Duax et a l ” 1985; Korach et 
a l . , 1985)• But since Z-pseudo-DES and E一:pseudo一DES were bent 
likewise without losing much binding a f f in i ty (as in INDC)? 
i t was calculated 七 h a t Z—pseudo—DES (but not E-pseudo-DES) 
could relax into a metastable s ta te with an extended planar 
structure similar to DES. This could explain why Z-pseudo-D£S 
was biologically ac七ive and lends support 七 o the hypothesis 
七 h a t the receptor does not require a f l a t molecule for high 
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Fig. 23 : Bis-nor-YCK and i t s analogues (K.F. Cheng, personal 
communication). The dosage shown is 七 h e highest dose (+ve》 
or (-ve) tested in at least on group of ra t s (n二5)• 
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This opens the way for considering the use of estrogenic 
compounds l ike YCK which is structurally alien to the estrane 
or triphenylethylene design. 
. • • ：' ' • • ‘ . ‘ •. ： 
The R — configuration of YCK (the s te r lc centre 
refers to C一6 position) dictates that the free indole must be 
under the tetracycl ic plane to be active. While R- and S-
七 y p e configurations could exist in the bent position, they 
place 七 h e indole nitrogen to opposite directions. Viewing 
from a 2—D plane, R-YCK (6a—indole) points the nitrogen atoms 
"down-page
11
, whereas, S-YCK (6/5—indole) points 七 h e nitrogen 
atoms "up—page"/ Now that we agree 七 h a t 七 h e 3-OH group 
determines binding and 170—OH group determines activation. 
But according to Belleau's hypothesis of Specific 
Conforination Perturbation, in order 七 h a 七 a ligand could exert 
七 h e f u l l spectrum of act ivi ty (Jordan 1984a, 1984b), there is 
s t i l l room for improvement by considering additional binding 
or act ivi ty s i tes , 
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An alternate receptor model based on known preference of high 
a f f in i ty ligands proposed by Durani et a l . , (1989) consisted 
of 5 subsites• By f i t t ing YCK into this multi-site model整 







i t could be envisaged that the primary binding s i t e is 
reserved for the 3-OH on subsite A. This would bring the N-
nitrogen atom close to subsite B. Since only the 6R 断 
configuration is active, 6a-indole would require a subsite E 
or C to be situated below the plane in order to get in close 
contact with the 6
1
-OH and the N
f
-nitrogen. Hydroxylation on 
2,5•-positions would direct YGK out of the 5-domain model and 
move the nitrogen atoms away from subs i t es B and E or C 
respectively. Substitui七ion on N1-nitrogen, whatever the size 
and polarity (see Table 1) would hinder i ts close contact 
with subsite E or C. The involvement of the lone pair of 
electrons in Tam nitrogen for anti—estrogenic activity had 
been implied (Jordan and Murphy, 1990). Thus YCK could serve 
a s a probe to verify the rat ionali ty behind the 5-domain, 
model and at 七 h e same time providing some insight into the 
spatial arrangement of these subsites in 3-D dimension. 
We have shown that saturation of the C-9,10 double 
bond does not affect the arrti-implanta 七 ion activity (see 
Table 1) and that 9-Nor compounds are s t i l l fa i r ly active 
(Cheng et a l . , 1991) . Removal of 七 h e C-9 and C-10 carbons 
would give a tert-butyl group attached at C-7 and eliminated 
one chiral centre at C-10 at the same time. Provided that 七 h e 
C-6 indole and the C-7 tert-butyl groups are in a trans 
configuration, th is new analogue, 2—But—TCP, presents i t se l f 




resul ts showed that the synthetic route for 2-But-TCP goes 
and the product is active (K.F. Cheng, personal 
communication)• I t remains to be seen if receptor preference 
for a 6R - configuration holds out. 
於 丨 
L I I 1 
H 
2-But-TCP 
Non-hydroxylated YCK may bind irreversibly to 
additional ER binding s i tes resulting in a change in ER 
conformation not easily dissociable from YCK (Jordan, 1990b). 
Electron 七 : t r a n s f e r from the nitrogen atom to a subsi七e could, 
reinforce th is non-competitive binding. True to a l l indple 
compounds which are prone to be bioactive (acronycine and 
carbazole are anti-cancer), YCK may bind directly to nuclear 
s i tes in addition to ER binding. Alternatively, ER exposed to 
YCK, with or without conformational change, may bind directly 
to the nuclear matrix without competing with in the 
cytoplasmic compartment. Unoccupied estrogen receptor can 
bind directly to the nuclear matrix of estrogen sensitive 
t issue (Metzger and Korach, 1990). 
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4.6 Dissociated responses 
I t i s now broadly accepted that anti-estrogens^ 
which are also par t ia l agonists, could displace estrogen 
binding on ER in estrogen-sensitive t issues, thus 
contiribu七ing 七 o the impirovemerrt of the cancerous s ta te • But 
the binding specif ic i t ies of non-steroidal anti-estrogens 
could be quite different . Tam binds preferentially to AEBS 
and i t binds to ER with only a small fraction of the a f f in i ty 
manifested by E2. However, 4-OH-Tam binds even stronger than 
E2 to ER while reducing i t s a f f in i ty for AEBS by half (Lyman 
and Jordan, 1985). Thus a non—steroidal ligand might act 
through two different binding s i tes , depending on i t s s tate 
of hydroxylation. Even with the same hydroxylated compound, 
七 h e biological response could be quite different under in 
vitro and in vivo conditions. 4-OH-Tam could increase 
progesterone receptor synthesis in vivo but i t could not do 
so in vitro (Jordan et al,• 1985). By the same token, CI628 
(nitromifene, a triphenylethylene) did not e l i c i t an increase 
in progesterone receptor level in MCF-7 cel ls (Eckert and 
Katzenellenbogen, 1982) but i t could induce the de novo 
synthesis of ornithine decarboxylase in ra t uterus to the 
same extent (500x) as E2, though with a different time course 
(Rorke et a l . , 1984). 
While difference in structural feartures (estrane 
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VS triphenylethylene, hydroxylated or not) and binding si tes 
(ER vs AEBS) are ample reasons for divergent responses 
between E and AE, a more striking dissociation was observed 
with DES products.工t was mentioned above that the oxidative 
metabolites of DES gave r ise to IA and IB, both with the same 
binding aff ini ty as DES for ER. Dissociated responses between 
IA and IB became evident when other biochemical responses 
were examined. Whereas both IA and IB could increase 
progesterone receptor level and manifest the same level of 
nuclear receptor occupancy, only IA (see page 114) could 
stimulate glucose-6-phosphate dehydrogenase, but IB was 
stronger than IA in stimulating utreine DNA synthesis. With 
ornithine decarboxylase, both 工A and IB could only produce 
weak stimulation without much difference between them (Korach 
et a l . , .1985, 1991)• 
T hese two lines of evidence demonstrate vividly the 
dissociation in biocheiaicai responses elicited by part ial 
agonists, including AE. Dissociated responses suggest that 
although both E and AE action begin with receptor binding, 
the difference in potency is not merely a function of binding 
aff ini ty but should include the summation of individual 
biochemical processes, the relevant combinations of which 
w i l l determine various shades of biological response. Thus 
Tam seems to be a weak agonist because i t could s t i l l 
stimulate to a small degree uterotrophic response. I t is now 
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realised that E stimulates mitosis in endometrial and 
itiyometrial cel ls whereas AE stimulates mitosis in uterine 
epi thel ial cel ls with accumulation of uterine f luid (Rorke et 
a l . , 1984). 
YCK behaved like a fu l l agonist in stimulating 
glucose-6-phosphate dehydrogenase and orn i th ine 
decarboxylase, though not to the same extent as DES in the 
latter• However, i t was interesting to note that YCK and DES 
effects were not additive even at suboptimal doses in the 
stimulation of G-6-PD. In both cases, while YCK can override 
the lack of response in Tam, i t could also limit the maximal 
response el ic i ted by DES when the two were administered 
together. I t seems to suggest that YCK could dominate 
receptor binding and i t t i l t s the equilibrium to a non-
specific conformational perturbation that could only afford 
suboptimal biochemical responses irrespective of an optimal 
level of E being dosed. This is a different kind of 
dissociation not observed in Tam and DES metabolites.工七 
strongly hints at additional binding or activation components 
in ligand-receptor processing. While YCK binding to ER had 
been reported earl ier by others (Wang et a l . , 1990) we point 
out here that i t s binding af f in i ty i s much weaker than i t s 
biological potency (anti-implantation, uterotrophic 
act ivi ty) . With the liver microsomal preparation, containing 
AEBS, binding kinetics between Tam and YCK seem to be 
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different• Anti-proliferative effect of YCK in MCF-7 breast, 
cancer cel ls might possibly act through AEBS, At present, we 
can not read too much into these early biochemical results„ 
Further studies in dissociated responses of YCK, using 
improved analogue would herald a f ru i t fu l f ield of 
investigation from which a new chemical probe could be 
expected. 
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4.7 Summary 
1. Yuehchukene (YCK) is a bis-indole alkaloid isolated from 
Murrava paniculata (L.) Jack and exhibited very potent 
anti-implantation activity irr ra ts . 
2 • Yuehchukene has a conservative molecular design and has 
an indeno-indole basic structure which is not known 
among other bioactive indolyl alkaloids. 
3. Yuechukene is the product of acid-catalysed 
dimerisation of two isoprenylindoles under in vitro 
condition. ' 
4. Yuehchukene is likely to be a non-enzymatic 
condensation product from i t s precursor in vivo. 
5. Yuehchukene carries 4.5% estrogenic - activity in 
uterotrophic activity assay and acts like a part ial 
estrogen. 
6. Anti-implantation activity assay of the enantiomeric 
isomers of R(+)-camphor-YCK and s(-)-camphor-YCK 
indicates that the configuration of active YCK should be 
represented as the 6R - form. 
7. Yuehchukene binds to the estrogen receptor and i t 
requires around 0 .,3 /iM to reach 50% inhibition of 
• . . . » . • 
estrogen binding. 
8 . 工 n liver microsomal preparation, yuehchukene is able to 
displace labeled tamoxifen binding with an effective 




9. Ornithine decarboxylase activity assay indicates that 
yuehchukene behaves like a weak estrogen as i t could not 
I 
fully stimulate uterine polyamines synthesis. 
10. Glucose—6—phosphate dehydrogenase activity assay shows 
that yuehchukene could not stimulate a fu l l response as 
induced by DES and co—administration with DES at 
suboptimal dose shows that the activity is not additive. 
11. Yuehchukene has anti-proliferative effect in MCF-7 
breast cancer cell line indicating that YCK might act 
like an anti-estrogen. 
12 • Saturation of the cyclohexenyl double bond does not 
affect 七 he anti—implantation activity and 7-Nor 
analogues are s t i l l fair ly active. These results 
indicate that YCK might require only a simplified 
molecular design in order to be active as demonstrated 
by the compound 2-But-TCP (K.F. Cheng, personal 
communication) • 
1 3 . Improved YCK analogues provide new chemical probes to 
study 七 he dissociated responses of estrogenic 
compounds with a view to select improved E or AE in 
endocrine therapy of estrogen-dependent diseases. 
13 3 
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